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ABSTRACT
The activities of pseudocholinesterase (pehE) were compared in the !Coelum
of type I and type tI diabetic patients and non-diabetic subjects. Both type
I and type II diabetic PAtients showed incre~ serum PChE adi\'jty con-
comitant with the presence of hyperlipidemia. Pearsons correlation anAlysis
showell a posili,'!! correlation between triglycerides (TG) and PChE in both
type I (P=0.499) and lype II (P=O.526) diabetic pAlienls.
Induction of chemical diabetes in rats with Sltepto:oloein (5Z) and flllaxan
also increa.sed the serum PChE aclivit)' which pllraUeled the development of
diab<!tc-s mellitus. Serum triglyceride!!, ap~B containing lipoproteins (total
low density lipoprotein~ TLDL) and glycerol concentrations &.150 increased.
When the hyperglycemia producM in slreplozotodn induced diabetic rau
was controUcd by administration of insulin, the levels or TG, glycl!rol and
PChE activity all reverled to pre-diabetic kvels. When insulin treatment wa,s
withdrawn hyperglycemia developed again and serum levels of PChE aclivity,
TO, glycerol and TLDL also increased. The concenhation ofTG in the liver or
SZ-diabetic rats W&$ significantly higher compared to the normal rats. Adipose
tissue and liver PChE activity were not significantly different in these SZ·
diabetic rats.
Gold thioglucose (GTG) trealetl mice, which ale type II diabetic models,
also showed a significant increL'5e in serum PChE activity and lipids similar
to the SZ induced type I diabetic models. Inhibition of PChE activity in
GTG treated mice W&ll &$SOCiated with a decrease in serum glycerol, TO and
TLDL levels. Liver PChE activity was markedly higher in the GTG treated
mice comp!ued to the untreated control mice. Administration of Iso-OMPA
to GTG treated mice inhibited both liver and adipose tissue PChE atti"ity.
Heparin treatment ofSZ-diabetic rats significantly redllced serum TG levels
without affecting PChE activity, cholesterol, HDL·C or TLDL levels.
Administration of Iso-OMPA, a spedfic PChE inhibitor. to 5Z·diabetic
and normal rats ptoduted a significant reduttion in serum TG, glycerol and
TLDL le\·eI8. Withdrawal or isa-OMPA inhibition in the diabetic mts resulted
in an increase in the lipid levels to those previously present in the diabetic
state. PChE activity and TG levels were also reduced in the iso-Or-,-IPA treated
diabetic and normal rat livers compared to the untreattd rats. Adipose tissue
PChE activity was also inhibited in the iso-OMPA treated diabetic and norma.!
rat
Inhibition of PChE activity with iso-OMPA failed to produce Iln accumu-
lation of choline or cholincslers in the liver, serum or to affett their excretion
in the urine of norma.! rats.
The results indicate that changes in PChE activity parallel changes in TG
metabolism, particularly during the perlurbanc<'S that accompany diabetes
mellitus. Whether PChE has a tole in very low density TG (VLOL-TG)
metabolism remains to be determined but is of considerable interest.
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Chapter 1
INTRODUCTION
1.1 Pseudocholinesterase
Sir Henry Dale in the early ninteen hundreds was the first to suggest the pres-
enCl! of lUI enzyme in the blood capable ofhyrirolyzing acet;ylchoJine into choline
and acetic acid (SilVEr 1974). This view was wnfirmed over the years by sev'Jral
workers. Stedman et af, (H132) prepared the first crude extract artbe acetyl-
choline hydrolyzing enzyme from horse serum and called it "Choline ester!lSe".
A few years later Alles and Hawes (1940) demonstrated the existence of two
choline esterases in man: one in the erythrocytes and the other in the plllSma.
Subsequently, Mendel and Rudney (1943) sbowed that the mum cboline es-
terase was a non-specific enzyme that hydrolyzed not only choline esters but
also non-choline esters like tributyrin, tripropionin and methylbutyrate. This
non-specific enzyme they called" Pseudocholinesterase". Thus these two inves-
tigators distinguished between the two cholinester8Ses as true cholinesterase
(acetylcholine hydrolase: EC.3. I. 1.7: acetylcholinesterase AChE) and Pseu-
docholinesterase (acylcholine llCylhydrolase: EC.3.U.8: PChE). AChE and
PChE in vertebrates <:an be differentiated from other esterases by being inhib.
ited by 10-5M eserine and physostigmine. Furthermore PChE can be differen-
tiated from "simple" esterases and AChE by the selective and irreversible in-
hibition wi~h te~rajsopropylpyrophosphoramide (iso-OMPA) (Aldridge 1953).
In the sera of most mammals, <:ho1ines~erase ac~ivity is due solely to PChE
(Silver 1974).
1.1.1 Multiple forms of PChE
The early work orSurgenor and Ellis (195<1) suggested the PChE adivity orhu-
man serum was due solely to a single protein. But Hanis eI al. (1962) resolved
four bands of a<:tivity (termed CI-C4) in the region between Q'~ and ,8-globulins
using two-dimensional filter pap!!r starch gel!!lectrophorcsis. In 5-10% of nor-
mal population a slow moving fiflh band (C5) was observed (JuuI1968). CI
band moved the fastest and C4 the slowest. C4 was reported to bl:! the major
component as it contained 00-95% olthe esterase adh'ity found in the plasma.
C4 had the highest molecular weight (340,000-361),000 daltons), the weighls
of the other fractions deaeasing in the order C3 170,000; C2 110,000j and Cl
82,000 (La Motta et af. 1970). lsoenzymes or PChE have also been delected
in the horse serum (Reiner et al. 1965). The number of isoenzymes of PChE
reported varies with the type of methDd employed for its separation. Hess
et 01. (1963) obh.ined 2 bands with acetylthiocholine as substrate for rabbit
serum on starch gel but no bands were detected with butyrylthiocholine (BTe)
as substrate. Juul (1968) separated 12 activity bands from hUffiM serum on
polyacrylamide disc electrophoresis with butyrylthiocholine and copper stain·
ing, while DIlS and Liddell (1970) using tbe same electrophoretic method but
a different stain (a·naphthylacetatt) detected only ·1 bands. La Motta et 0/.
(1968, 1970) suggested that the different iwenzymes could be intercom'erted
under experimental conditions, thus the multiple forms were just molecular ag-
gregates of a common polypeptide subunit or degradation products (Lockridge
and La Ou 1982)
Several genetically determined variants of PChE have been found in man.
These are the atypical pehE variants like (a) the dibucaine r(!Sislant, (b) flu·
oride resistant and (c) the silent·gene type. Homozygous for tbese variants
urfer from prolonged apnea when administered succinylcholine (suxameth~
nium) (Silver ]974). These variants differ in their activity towards their sub-
strates and inhibitol1i. The atypical or Dibucaine-resistant variant is unable to
hydrolyze a number of substrates, including succinylcholine at a normal late
and is resistant to PChE inhibitors. This resistance is expressed in terms of
Dibucaine number (ON) which is the % inhibition o( the enzyme produced
by dibucaine (lO-IiM) (Kalow and Genest 1957). The homozygous for usnkl
pehE have a ON of about 80. Those with a ON below 20 Were reported he--
mozygous (or the atypical enzyme and 8 DN between 52·69 were heterozygous
(or the usual and atypical pehE. The DN number does not depend on the
cholinesterase level and the degree of inhibition is constant for anyone indi-
vidual. McGuire el al. (1989), demonstrated the replacement of aspartic acid
by glycine at position 70 in the primary sequence of the usual PChE polypep-
tide. This substitution of a neutral amino acid for the acidic one may accvunt
for the redu(·ed affinity of the "atypical" form for choline estern and dibucaine.
Harris aud Whittaket (1961) identified a variant which had a low-fluoride
number but 8 dibucaine number slightly lower than the normal. Us ac::vily
towards succinylcholine was greater than the dibucaine resistant but lower
than the normal. This variant they called /luoride·ruislanl.
LiddeD el 01. (1962) reported a third variant. In this case the serum con-
tained a protein very similar to normal PChE wilhout any detectable enzyme
activity. The gene responsible for such a protein was termed a Jifenl gene.
1.1.2 Properties of Purifted PChE
PChE has been purified from the feUewing sources: human serum (OM &
LiddeU 1970, ~fuensch el of. 1976), horse serum (Lee &. Harpst 1973, Main et
al. 1974), rabbit liver (Rush et al. 1980) and porcine parotid gland (Tucci lot
Seifter 1969). PChE from bacterial sources have also been purified. Nagasawa
et af. (1976) purified PChE from Pseudomonas and P. polycofor.
Most oftb!: information about PChE has been obtained with purified hu-
man serum PChE. Highly purified human mum PChE has a molecular weight
between 345,000 to 365,000 daltons and appears M a single band correspond-
ing to the C4 band on polyacrylamide gel electrophoresis (Muensch el al. 1976,
085 and LiddeD 1970). Lockridge et al. (1979) suggested a tetrameric struc-
ture for PChE. It is a soluble, globular G4 protein with 4 identical subunits.
The subunits ale ananged as a dimer of dimers, with each dimer having iden-
tical subunits joined together by interchain disulfide bonds (Lockridgt 1988).
Each subunit has 574 amino acids and a molecular weight nf 85,000 daltons
(Muensch d al. 1976). The interchain disulfide bond, seem 10 stabilize the
entyme against heal inactivation and ate not necessary for the tettameric or-
ganiulion of the subunits or fot the activity of the enzyme molecule.
1.1.3 PChE Gene
Two genetic lad determine PChE activity in the plasma. Locus Ellocated on
lhromosome 3 lontlols most of the genetic variants, like the usual, atypical,
nuoride resistant and the silent gene type (Brown dol. 1981;. The Sl.'Cond
locus E2controls the appearance of the C5 variant, the electrophorelkaUy slow
moving tetramer present if! 10% of the cauca.sians (Whitlekar 1986). Gene E,
which determinl!5 the production of the CS component of PChE is nonallelic
to the E1 gene of PChE (Harris .!l Robson 1963). Harris k Robson (1963)
also teported thst liubjeds whose serum lontain the C5 component ha\'e 30%
more plasma activity than others.
Liddell et 01. (1963) invl!Stigated tissues from a patient with the "..typi-
cal" type of serum PChE and found that the tissue PChE WM also similarly
"atypical", Thus, these investigators believed that onl)' one gene WII.'I respoll-
sible for the synthesis or the various isoenz)'metl. Human serum PChE hll.'l
been Sl'quencoo and cloned. The amino acid sequence of PChE ftom the liver,
serum and brain ate identical (Prody dol. J987, McTiernan doL 1987). be
human embryonic and adult PChE also appw to beKlentical. This (Oftlirms
that PChE hIS only one gene. Comparison or the amino acid sequence of
human PCbE and Torpedo AChE shows 54% bomoklgy. Human PChE h&S
38% 5equente homology with Drosophilia AChE, 28% with thyroglobulin and
48% with elfCtrie eel AChE (Lockridge et aL 1987). There is evidence that
monoclonal antibodies to humlR PChE do not cross react with red ceU ACh E
or y,ith rat PChE (Brimijoin d al. 1983).
1.1.4 Site olsynthesis of human PChE
It is generaUy believtd that in most species plasma PChE is synthesized in the
liver (Silver 1914). evidence for such a conclusion is based on the observation
th.llow le\'e1s of PChE activity are as.sociated with 6vtr distases (Antopol,
Sc.hrirrin k Tuchman 1938) and also with experimental ~ver damage (Brauer
& Root 1946). Decreased ~vels of PChE wu interpreted AS. reflection of
decreased protein s)'nthesis or the functional state of the hepatocytes (Brown
eI aL 1981). Khoury d oJ. (HI87) have also reported I change in the genetic
chamter from the o/ypica/to the normal form of PChE in the serum of 8.
patient after liver transplll.ntation. Theaminoacid sequence dedueed from the
eDNA clones showed that the liver and serum PChE were identical (McTierann
et c/. 1987, Prody tI ct. 1987).
1.1.5 Physiologicsl Function or PChE
Though thi! enzyme has a ubiqitoUJ distribution ils exact physiologic&! (unc-
tion is unclear. However, II. number oC possible roles have been put forth.
The potential role of PChE in hypcrlipoproteinemia and diabetes is of great
importance and is the main subjed of the present thetlis.
FunneU.ll Oliver (1965) proposed that PChE is involved in the homeostatic
mechanisms contIoUing the level of choline in plasma and acetylthiocholine in
the brain. This proposal WILS made on the assumption thai PChE hydrolyses
cholinesters and thereby conlrols the pla.sma choline levels. But the majority
of the cholinesters found in the plasma IIrc in II. bound (orm, like lecithin,
lysolecithin and sphingomyelin. None of these arc substrates (or PChE (Kutty
HI80). Thus the function of PChE in the homeostatic mechanism to regulate
plasma-choline is unclear.
1.1.6 PChE in lipid metabolism
Clitherow et al. (1~G3) proposed that PChE is involved in falty acid metabolism
in the Ih·er. Ballantyne (19G8) also proposed a similar function for the enzyme
in the adipose tissue. This assumption was made on the fact thai PChE
hydrolysed butyrylcholine, a toxic compound lhal could be formed from bu-
t}'fyICoA and choline. However, to date there is no evidence for the presence
of water soluble acylcholine in serum or tissues of humans or animals. This is
further supported by my finding thlll inhibition of PChE with iso-OMPA, 8.
specific PChE inhibitor, did not cause accumulation of any acylcholine esters
either in the lIerum or Iiyer nor excreted in the urine (KuUy, Annapurna &l:
Prabakaran 1989).
1.1.7 PChE and Low Density Lipoprotein (LDL)
Lawrence and Melnick (1961) sugge5t~ that serum LOL forrm an unstable
complex with PChE by a physical interaction there by resulting in the en-
~)'me being carried in an inacliye form in the circulation. This hypothesis W&5
supported by Dubbs (1066) who found an increase in serum pehE aetivily
after ultrasonication of serum. However, KuUy, Rowden k Cox (1973) pro-
posed that the association between PChE and LOL was very similar to the
interaction between AChE and acetylcholine (ACh). They hypothesized that
phosphorylcholine, the polar head group of phosphotidylcholine, like acetyl-
choline, can interact with the esteratic and anionie site or pehE, there by
blocking its activity. Alternatively, enu d al. (1978) reported that only 10%
of the total serum PChE could be rec:overed from LOL, which accounts for
only a fraction or the total PChE in circulation and thus does not assign"
role for the remaining unbound PChE. Kulty et al. (1977) demonstrated that
rals treated with neostigmine, a pehE inhibitor. showed a significant decrease
in serum ,8~lipoprotein (LOL or low density lipoprotein), associated with a
dec:reased incorporation of 31l-lysine into ,a·lipoprotein but an increased in-
corporation into a-lipoprotein (HDL or high density lipoprotein). ThllS, they
proposed that LDL is formoo from VLDL (very low density lipoprotein) in the
presence of PChE. A similar dose relationship i>etween PChE and LOL was
found in the serum of a patient with parathion poisoning who had low levels
of both. But during recovery both returned to normal with a concomitanl
decrease in HDL (Kutty el al. 1975).
1.1.8 PChE in Obesity and Hyperlipoproteinemia
Inueased serum PChE activity is common in conditions associated with ab-
normal lipid metabolism like hyperlipoproteinemia (Cucuianu el al. 1975,
1976, Chu et al. 19i8), obesity (Cucuianu et 01. 1968) and diabetes (Antopol
tI 01. 1937). The subjects studied also had elevated serum TG levels. In·
creased PChE activity wu more common in persons with type lib and type
IV hyperlipoproteinemia (Kutty et al. 1981a, Jain el al. 1983).
Increase in PChE activity has b~en reported in animals. ExperimentaUy
fattened pigs showed an increased PChE activity (Popescu tl of. 1976). Sim-
ilarly I<utty et a/. (19&lb) found increased serum and liver PChE activity
in genetically obese (ob/ob) mice. Lean mice treated with gold lhioglucose
(GTG) to induce obesity also exhibited. increased PChE activity (nutty et at.
I9Blb).
1.1.9 PChE in Food Assimilation
There have been reports lhat suggest the level of PChE activity mllY be innu-
eneed by the nutritional status. A significant decrease in PChE was reportClI
by Henderson et ell. (1971) in the serum and liver of rats when stll.Tved. Simi-
larly, liver PChE activity was found to be depressed in malnourished children
but returned to normaJ. with improved nutrition (Waterlow 1950).
1.1.10 pehE in Diabele.
In 1931, Antopol and ILSSOdates detected an elevated PChE I!.Ctivity in the
plasma of diabetics. This observation wlI.lIlater confirmed by F4ber (1943).
Kutty eI al. (1981b) haveclemonslratcd thatgenetk&lly diabetic: (dbfdb) mice
have higher serum and lh'er PChE: activities than lean controls. Deshmukh
(1986) reported an increase of l'lbout 75% PChE activity over the pre-diabetic
values il' rats made diabetic with alloxan with a concomitant increase in choles-
terol (LDL+VLDL) and decreased HDL·cholesterollevel.
1.1.11 Other Proposed Functions of PC hE
It has been postulated that PChE has m",re than olle function as indicated
by its presence in several tissues. Sa[\'ador &. Kuntzman (1965) found PChE
in the adipose ti~ue. Ballantyne (1\)68) reconfirmed this in the fat cells of
the adipose tisl;ue with histochl2minland biochemical methods that employed
specific substrates and inhibitors of PChE:. The pNsibility that PChE be-
haves like a lipase was suggested by Szendzikowki eI 01. (1961/62) using
antkholinesterases, By using nonspecific (eserine) and specific (Iso-OMPA)
inhibitors o~ PChE th.ese invl!sligaters observed an in vil'a and in vilro inhi-
bition in the lipolytic activity in the rat's aorta. Similarly Ii decrease in the
concentration ornonest-lrified ratty acid (NEFA) was also found in the plasma
of dog treated with cholinesterase inhibitors (Colville et 01. 19M).
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In a recent study hormone sensitive lipase was also found to exhibit esterase
activity (Tsujita d al. 1989). This esterase WM able to hydrolYIle nitrophenyl
butyrate and was inhibited by Diisopropylftuorophos;phue (DFP). Nitrophenyl
butyrate is a substrate and OFP an inhibitor of PCh&.
Lockridge (1982), enatonnet I.l Masson (1985) and Boopathy It Balsubra-
manian (1987) demonstrated that purified human pehE has both peptidase
and amidase activities. Loktidge d rd. (1980) also reported that pehE hy-
drolysed diacetylmorphine (neroin) in plasma.
1.2 Diabetes
Diabetes meUitus is a metabolic disorder occuring as a result of lack ofinsulln
5e(retion or tissue resistance to insulin and evidenced by changes in plasmA
concentrations of glucose, lipids and lipoproteins. h is onen characterised
by fasting hyperglycemia and gl)'C05Uria.. Himsworth in 1936 was the fint to
propose that two types of diabetes existed, differentiated by the presence or
absence of plasr.uinsuUn. The two types of diabetes c1l1SSified according to the
National Diabetes Data Group (NDOG 1979) are type I (insulin dependent
diabetes) and type II (non-insulin dependent diabetcs). Type J diabetits are
ketosis prone. The typ(l II diabetics are non ketotic and often associa.ted with
obesity. Clessification of diabetes according 10 the world hellith orgllnizlltion
(WHO) is shown in Table 1.1 and the criteria for the diagnosis of diabetes in
Table 1.2.
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1.2.1 Chemistry of insulin
In all species studied the insulin mole<:ule consists of 2 polypeplide chains A
and B conne<:ted by 2 interchain disulfide bonds. It has a total of Sl amino
acids and a molecular weight of 5800 daltons. Species differences occurs with
insulin isolated from various sources, with pig insulin being most similar to
human insulin. Porcine insulin differs from human insulin only in the tt'!Ollinal
amino acid of the B chain, where alanine replaces threonine. There are three
differences in the structure between bovine and human insulin ie at positions 8
(alanine replaces threonine) and 10 (valine replaces isoleucine) of the A chain
and amino acid 30 on B chain. Splitting of insulin inlo its constituent A
and B chains by cleavage of the di,lulfide bonds results in complete loss of its
biological activity.
Discovery of insulin was hailed as a cure for diabetes. But recent studies
show that it controls only the early symptoms of diabetes lind does not entirely
prevent the long term complications like coronary heart disease (ClIO), nen'e,
c}'e, kidney and skin disorders.
1.2.2 Biosynthesis of insulin
Insulin is synthesized by the ribosomes of the endoplasmic reticulum of the (1-
cells of the islets of Langcrhans. The produ.:.t is the insulin precursor-proinsulin
a single polypeptide with ~n approximate molecular weight of 9000 daltons.
Proinsulin 15 known to be synth<:lSised from large singlNhain precurso' pre-
proinsulin which hM a molecular weight of 11,500 daltons. It is converted to
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proinsulin by microsomll1 proteases within minutes of its synthesis. The proin-
sulin is converted to the active insulin in the golgi apparatus by proteolytic
cleavage of the c:onneding peptide (C-peptide) and stored in the secretory
granules. The free biologically inactive C-peplide is secreted in equal molar
ratio with the mature/active insulin. The human C-peptide consists of 23
amino add residues and has a molecular weight of 3021 daltons. It differs
from the pardne C-peptide by 10 residues and conbins 2 amino acids less.
Release of insulin involves migration of the se<:retory granules to the plasma
membrane of the 13 cells where its membrane fuses with the plMma membrane
and discharges its contents (both C-peplide and insulin) into the extracellular
spaces. This process has been termed as emiocytosis (Randle &: Hales 1972).
The amount of insulin secreted by the pancreas per dAy hl&S been eslimaled
as 1 l,nit/kg body weight, which for a 60 kg normal adult amounts to 2.5 109
protein. Circulating insulin is degraded mainly in the liver and a small por-
tion in the kidney by the enz)'me glutathione insulin lranshydrogenase by the
cleavage of the disulfide bonds that conneel the A and B chains, The A and
B chains are further degraded by proteolysis. Half life of insulin is 3-5 min.
1.2.3 Mode of Action of insulin
The major met':!bolic action or insulin occurs in the muscle, adipose tissue
and the liver. It seems to be comparatively inactive in the erythrocytes and
gastrointestinal tract. Insulin firmly binds to a specific receptor which is a
glycoprotein on the plasma membrane or its target tissues. In the adipose
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tissue it facilitates the transport of glucose across the cell membrane and thus
its phoshorylll.tion to glucose-8-phosphate (G-6-P). The metabolism of G-6-P
to &Cetyl-eoA IIffeds fat metabolism in a number of ways: (II) metabolism
of glucose along the hexose monophosphale shunt provides the coenzyme
Np.DPH required for fatty acid synthesis, (b) the metabolism otglucose via the
Embden-Meyerhof pathway generates a-glycerol phO$phale which is used for
the esterification oi fatty acids to form TG and (c) the metabolism of glucose
also provides two-carbon fragments for fatly acid synthesis (Smith 1989).
Insulin is also known to dear the circulating TO by activation of LPL. LPL
hydrolyses the TO in the chylomicrons and VLDL which results in the release
of free fatty acids {FFA). These FFA enter the adipocytes where they combine
with the glycerol generated by glucose metl\bolism to form TG which is de-
posited in the adipocytes. Insulin is known to inhihit adipose tissue lipolysis.
Thus in short insulin affects the adipose tissue metabolism by promoting glu-
cose transport into the ceU, stimulates fatty acid synthesis, inhibits lipvlysis
and activates LPL.
Insulin is not necessary for the transport of glucose inlo the liver since the
hepatocytes are freely permeable to glucose. Within the cell insulin activates
glycogen synthetase and directs the Row of glucose to glycogen forffil\lion.
Insulin increascs glucokinase activily which phosphorylates glucose to G-6-
P and its metabolism via the glycolytic pathway. Insulin deficiency reduces
phosphofructokin8.Ge (PFK), the second rate limiting enzyme or the glycolytic
pathway and impairs glucose entry into the metabolic pathway.
Insulin inhibits gluconeogenesis by the suprtsSion of pyruvate kinase (PK)
and phosphoenolpyruvate carboxykinase (PEPCK), which are rate limiting
enzymes. In the liver insulin stimulates fatly acid synthesis by increasing the
activity of ILCetyl·CoA carboxylase and generating coenzyme NADPH (hydro-
gen donor) by induction of pentOSl! phosphate pathway and NADP+·malate
dehydrogenase (ShaCrir, Bergman k feUng 198i).
In insulin deficiency the release of fatly acids from the adipose tissue is
greatly inneased. The liver disposes them in a number of ways. Some are
completely oxidized to CO2 and water. The majority are oxidized to two
carbon fragments, these are directed into ketogenesis or glyceride synthesis.
Insulin fadlitates the transport of a variety of substances acrms the pla.sma
membrane other than glucose. like Na+, A"·, inorganic phosphate ions, amino
acids and calcium ions. It also helps in protein synthesis. Insulin is thus an
anabolic hormone causing increased carbohydrate metabolism, glycogen and
lipid synthesis, amino acid up take And protein synthrsis (ShaJrir. Bergman.\:
FeUng 1981).
1.3 Lipoproteins
1.3.1 Lipoprotein structure
Basically all lipoproteins have the same Cundamental strurtute. From elec·
tron microscopic studies it appe.lLlS that they are spherical particles, with the
nonpolar trigl)'cerides and cholesterol esters Corming the central lipid core,
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Table 1.1:
tClassification or diabetes mellitus according to WHO
A. Clinical classes
Diabetes mellitus (DM)
Insulin~dependent diabetes mellitus (lDON)
Non-insu1:!.;t-dependent diabetes mellitus (NIDOM)
(a) Non-obese
(b) Obese
Malnutrition-related diabetes mellitus (HRDM)
Other types of diabetes associated with certain
conditions and syndromes:
0) pancreatic disease
(2) disease of hormonal etiology
(3) drug-induced or chemical-induced conditions
(4) abnormalities of insulin or its receptors
(5) certain genetic syndromes
(6) miscellaneous
Impaired glucose tolerance (IGT)
(a) Non-obese
(b) Obese
(c) Associated with certain conditions and
syndromes
Gestational diabetes mellitus (GD~l)
B. Statistical risk classes (!>ubjects with normal
glucose tolerance but substantially increased
risk of developing diabetes)
Previous abnormality of glucose tolerance
Potential abnormality of glucose tolerance
'Taken from "The Diabetes Annual" Vol 3.
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Table 1.2:
'Criteria ror the diagnosis or diabetes NDDG \'5 WHO
Plum glucose lD&/lOO III tIllllol/i).
:Jul glucolle tolerance ust
Class Fasting Hid-tut 2-l!our tut
Norm:al
ICT
Diabetes'"
Non-:1iagnolltie
WIlO
<115«6.4) and <200«11.1) Ind (1/.0«1.8)
<140«1.8) and ?:200(Hl.l) Ind 140-1990.8-11.l)
2:140(.~7.8) or 2:200(2:11.1) and ~200(Ul.l)
all other combinuiOnl of falting. mid-test .nd
2-h values
NOl'1lll1···
leT
Diabetes"
<l40«1.8)
<140«7.8)
2140(2.7.8)
and (140«1.8)
and t4CH990.8-1I.1l
or ?:200<?:11.l)
"'The _lit vdu.. were COlI.puted b, dividing 11I&/100 III valuu by 18.016
the number of IIg of glueol' in 100 1:11 of • I-~"l lolution) .nd rounding
to the nnrut 0.1 1lIll101/1. ""HO obtained _111 vlluu by dividinll1lgl
100 1111 v.lues by 18 and rounding to the nurest 1 ~1/1.
**NDOC and WHO r.quire both the futing and 2-h vatu.. to classify ..
SUbject, except "hen the fasting is ?: 14011&/100 .1, wich by itself is
diagnocric of dilb.t.lI.
"*.Although lo/HO does not define a 'normal' OGTT, the term is used here to
include subject, vIIo do not meet criteria for di.bet.s or ICT.
'raken frOlll "The Diabetes Annual" Vol 3.
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sunounded by an ampbipathic layer of phospholipids, free cholesterol and
apolipoproteins which keeps the particle in solution in the plasma (Jaekson eI
al. 1976). Composition and functions of lipoproteins are as shown in Tables
1.3 and 1.4 respectively.
1.3.2 Lipoprotein metabolism
Chylomicron metabolism
Lipoproteins in man are synthesized by the liver and secreted into the plasma.
Fig 1.1 presents the general pathway of lipid metabolism. Chylomicron!, the
largest and lightest of the lipoproteins, are synthesised mainly in the small in-
testine and transport the exogenously deril'cd (ats (triglycerides) to the liver.
It contains apo-B18 l\5 its main prolein. Following secretion into the pllLSma
these lJarticles rapidly acquhe apo-CII and aJ)<>E Crom the HOL in circula-
tion, Triglycerides (TG) in the chylomicrons are hydrolysed by the lipoprotein
lipase (LPL) present on the endothelial surfaces o(the adipose tissue, cardine
and skeletal muscle. Apo-CII in the chylomicrons activates LPL (Havel eI af.
1970). The hydrolysis ofTG by LPL results in the liberation offatty acids and
monoglycerides. The fatty acids arc taken up by the muscle or the adipocytes
where they arc oxidized or re-esterified and slored. As thc TG corc is depleted,
the chylomicrons dcerease in size, Thesurfnee materials, mainly phospholipids,
free cholesterol and apo-C are transfered to HOL. These chylomicron particles
known as chylomicron remnants (Redgrave 1970) arc proportionately rich in
cholcsterolcsters, apo-B and apo-E, The remnants are taken up by the liver
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ceUs, by receptor (which recognises apo-B and ll.po-E) mediated endocytosis
(Brown, Kovanen &t Goldstein 1981) and degraded in the IY8Qsomes. Chy-
lomicrons in man are rapidly cleared from the blood with a half liCe of 4·5
min.
Very low deneity lipoprotein (VLDL) metabolism
VLOL's are smaUer than chylomicrons ll.nd are the major transport vehicles
to the extrahepatic tissues for the endogenously synthesised TG. They contain
apo-BlllCl as the chief apoprotein. The fatty acids (FA) used for the synthe-
sis of TO are derived Cram two sources: (I) from acetyl-CoA derived from
carbohydrate metabolism and (2) uptake of FA from the circulation. Under
normal conditions the first source is dominant when circulating FA is low.
But in conditions like diabetes meUitus, fasting or high fat diet, the circulat·
ing FA is high, and forms the main source of TG fatty acids. Shortly after
secretion, VLOL particl~s, like the chylomicrons, acquire apo-CII and apo-E
from the circulating HoL. VLDL·TG is hydrolysed by LP:". VLOL decrenses
in size, ib density increases and its surface phospholipids and cholesterol are
trllnsfered to the circulating HOL. The product formed is termed intermediate
density lipoprotein (IOL). Lecithin cholesterol acyl transferase (LCAT) ester-
illes the cholesterol transfered to HOL from VLOL. The newly synthesised
cholesterolester is transfered back to IDL. In rats lOt is taken up entirely
by the liver and about 10% is converted to L01 (Eisenberg 1979). The fT)L
particles in man are finally converted to low density lipoproteins (LDL). This
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lipoprotein frattion ill made of mostly cholesterolester and apc;B. LOL deliv-
ers cholesterol to the extrahepatic. tissues and liver. According to Goldstein
and Brown (1974) these LOt particles are removed from the circ.ulation by
receptor mediated endocytosis in the peripheral tissues. The number of 1.01.
binding receptors on the cen surfate appears to be regulated by the need for
cholesterol by the ceU. VLDL has a hAlf life of about 6 h in the circulation
(Eisenberg 1019).
The HOt particles are synthesized and secreted both from lhe liver and
intestine as discoid particles containing phospholipids, cholesterol, I\po-AI and
ape-All as the major apoproteins (Hamillon et al. 1916). Studies on perfused
rat liver by Hamilton et al. (1916) indicate that these discoid particles are
rapidly transformed into spherical forms in the plasma. The mosl important
feature of this transformation is the esterification of its cholesterol by lecithin
cholesterol acyl transferase (teAT) upon activation by apo-AI (1101.). 1I0L
functions in the transport of cholesterol from the \'arious peripheral tissues to
the liver 10 be disposed. This fU:lclion of HOL is refered to as "reverse choles-
terol transport" (Glomset 1080). HOL has a half life of 3·6 days (Schaefer
1979).
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1.4 Lipoprotein Metabolism In Diabetes Mel-
litus
1.4.1 Type II (NIDDM)
Abnormal lipoprotein metabolism is II. common (eature in type II diabetes,
which contributes significantly to the increased risk for atherosclerotic heart
disease. In the Dlajority of the studies on type II diabetic patients, the most
typical lipoprotein alteration is the elevation in serum VLDL and TG. (Nikkilll
&; Kr.kki 1973, Kissebah et al. 1982, Dunn eI 01. 1984, Ginsberg &: Grundy
1982). The feason for the increase in serum VLDL·TG has been suggested
to be increased synthesis and deueasoo clearance (Nikkila 1985). Taskinen
(l(86) reported increMed lel'els of plasma fatty acid in the type II diabetic
patients and concluded that the o\'erproduction of VLDL·TG was due to the
increased flux of fatty acid to the li\'er. BrunzeU et al. (1985) also reported
that I,he major c.ause of hypertriglyceridemia in type II patients may be due to
increaserl synthesis of VLDL-TG as a result of increased flux..,f fatty acid to
the liver due to obesity and insulin resistance. Ho.....ever, Howard et al. (1083)
found no significant rise in VLDL-TG in ,subjeds with mild hypergi)·cemia.
This suggested thai increased VLDL·TG production was in some way related
to uncontrolled hyperglycemia. This vicw was supported by the obsernlions
that overproduction of VLDL decreases upon glycemic control, regardless of
the type of therapy (Nikkila & Kekki 1973, Kissehah et al. 1982, Ginsberg
k Grundy J982, Taskinen et ul. 1986). Dunn et al. (1984) also reported
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that poor glycemic control could contribute to VLDL-TG overproduction and
reduced fractional catabolic rate (FeR). A decrease in VLDL-TG overproduc-
tion produced by effective glycemic control could be related to decreased. (atty
acid mobilization from the adipose tissue. Reaven (1987) suggested that ele-
vated plasma fatty add in the presence of circulating insulin levels may lead
to excessive production and secretion of VLDL-TG by the liver and hence to
elevated plasma TG concentrations.
Decrea',il!S in lipoprotein lipase (LPL) in the adipose tissue and skeletal
muscle have befn observed in uncontroUed diabetes (Pykll.listo e/ af. 1975).
Decrease in LPL activity is consistent with decreased VLDL c1carance in type
II diabctes (Taskinen et af. 1986, Brunzcll et al. 1979). These findings are also
consistent with the finding that glycemic control increased VLDL c1carancc
and LPL activity regardless of the type or therapy (Taskinen e! al. 1986). The
clearance ofVLDL·TG could also be affected by the abnormal compositio:l of
VLDL in type II diabetes (Taskinen et al. 1986).
LDL metabolism
Type II diabetic patients may exhibit normal or slightly increased levels of
LOL (Kostncr k Karadi 1988). An increase in the concentration of TG in
LOt has bl'!en reported by Taskinen et al. (1982). Gonen et 01. (1985) showed
that LOt (rom type It diabetic patients had an increased ratio of cholesterol to
apo-B, with altered metabolic properties. This is supported by in l,jlro studies
showing a decreased binding o( LOt isolated from hypertriglyceridemic dia-
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betie patients to skin libroblllSts (Hiramatsu et at. 1985). These investigaters
showed that the decrease in binding was inversely related to TG/protein ntio
in LDL.
HOt metabolism
Another characteristic finding in type II patients is decreased levels of I1DL-
Cholesterol (HDL·C) (Reaven 1987), A great deal of information is available
suggesting an inverse relationship between plasma TG and HDL-C concen-
tration (Nikkila 1981). Thus the caum that elevate plasma TG may also
be responsible for tht lowering of HDL-C levels, According to Nikkila (1981)
low levels of HOL levels in t}'pe II diabetes are assodated with obesity and
hypertriglyceridemia, Since most of the type II diabetic patients are obese
and hypcrtriglyceridemic, alterations in HOL levels may be due to insulin de--
fidency or more commonly to insulin resistance and hyperinsulinemia (Nikkila
1981). Glomset (1980) suggested that I10L-C levels ate inversely related to
both body weight and serum TO, therefore obesity and hypertriglyceridemia
may playa role in maintaining HDL-C levels. Hepatic lipase is elevated in
the t}'PC II diabetic patients and could accelerate removal of HDL-C from the
plasma and thus re<luce HDL levels (Nikkila 1981).
1.4.2 Type I (IDDM)
These patients are usually nol obese and characterised by insulin deficiency.
They therefore require insulin therapy lind untreated diabetic patients ,:har-
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acteristica.lly develop severe keto&Cidosis. In addition, this type of diabetic
patient also develops severe hyper~pidemia in the absence of glycemic con·
trol. Metabolic control is usually judged on the basis DC blood glucose, HbAle
lind urine glucose levels. It has been well established that plasma lipid al;>.
normalities are related to the degree or glycemic control (Sosenko d al. 1980,
Lopes·Virella tl al. 1981 1 Glasgow d al. 19~1), Short term improvement
in gly<:emic control by continuous ~ubcutaneous insulin infusion (CSII) ther-
apy by Hershcopf tl a/. (1982) reduced plasma lipid concentrations (TG and
:holesterol) withir. 2 weeks. According to Sosenko eI a/. (1980) "poor control
of blood glucose is conducive to accelerated atherosclerosis in diabetes mel-
litus" due to hyperlipoproteinemia. Extreme elevations in VLDL levels are
reported to be characteristic of diabetic ketoacidosis, a state in which insulin
concentrations are minimal (BrunzeU el 01. 1985). Hypertriglyceridemia in un·
controlled type I diabetl!S is due to combination of increased production and
decreased clearance (Nikkila et al. 1977). Increased production of VLDL in
type I diabetes is due to thl! increased mobilization of fatly acids from adipose
tissue.
DeCfl!ased activity of LPL in type I diabetic patier.ts affetts the clearance
of VLDL-TG from the circulation (BrunzeU, Porte &. Bierman 1979). LPL
activity is reported to be decreased in adipose tissue and skeletal muscle in di-
abetic patients (Taskinl!n 1987). Post heparin Iipolylic activity has been found
10 be decreased in type I diabetic patients which normalizes aCter treatment
with insulin (NikkiJa et af. 1977).
27
Sosenko d aL (1980) observed an increMe in futing pluma cholesteI<H,
TG, LOL and VLDL levels with hyperglycemia. LOL hu ~n reported to
be increased. in UDcontroUtd type I diabetic paHents (Glasgow et 01. 1981,
Sosenko d al. 1980, LOp&Virdla d al. 1981). Lo~Virella eloJ. (1982)
demonstrated tbat the LOL Crorn uncontroUM diabetic patients are taken up
and degraded by the normal fibroblllSts at a lower rate than LDL from the
normal or controlled diabetic patients. Hence these investigators spe<:ulated
that LOt had an altered composition in patients with poor metabolic control.
A large number of reports show a correlation between low levels of plasma
HOL and untreated diabetes (Sosenko el 01. 1980, Lopes-Virdla d of. 1981,
GlllSgow d al. 1981). Howe\'er IIOL increases on insulin therapy reflecting a
degree of glycemic control (Kostner L:: Karadi 1988). Decrease in LPL activity
as a result of insulin deficiency could be one of the factors responsible for the
reduced HOL le\'els (Taskinen 1987).
1.5 Animal Models of Diabetes
1.5.1 Type I Diabetic Models
A model resembling human insulin dependent or type I diabetes can be cre-
ated in animals by treating them with agents like alloxan, strepto%otodn (SZ)
or anti·insulin serum. Alloxan is known to function by the inhibH!or. Jf the
enzyme glucokinase, present in bolh the liver and pancreatic ,8·cells. Alloxan
oxidises the ·SH groups al the: sugar binding site resulting in the inhibition
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of glucose induced insulin secretion and produces neerosis oC the pancreatic
p-cells due to iu toxic elTed (Lenzen &: Panten 1988). AllozoR diahtteJ in an-
imals, presents the typical symptoms of type I diabetes in man such a.s weight
loss, polydipsia, polyuria, glycosuria, ketonuria, hyperglycemia and ketone-
mia (Malaisse 1982). Fadors such as diet, age and animal species affed the
dose required for the induction of a diabetic state with alloxan (Webb 1966).
Strcptozotocin has largely replaced alloxan, as it isll.'SS toxic and its effects are
reproducible. It allows the induction of diabetes of predictable severity (Junod
et al. 1969). The diabetogenic action of SZ is mainly due to its specific cyto-
toxic action on the ,6'-cC!lls of the islets or Langerhans where it produr.es rapid
and irremsible netrosis (Junod et al. 1969). The inten!ity of the damllgc
caused can be graded according to the dosage used, thus resulting in the pro-
duction of diabetes of graded severity (Junod dol. 1969). The re~·ponse to SZ
action on the .a-cells is triphasic: initially insulin secretion is inhibited leading
to hyperglycemia with increase in plasma free fatty acids and ketone bodie~,
rollowed by extreme hypoglycemia and finally an irreversible hyperglycemia
within 24 hr after the treahnent (Junod et 01. 1969). High doses of 52 (>
100 mg/kg body wt.) produce hyperglycemia, hyperketonemia and hyperlipi·
demia in rats (Schein et al. 1971), while low doses produce hyperglycemi& but
rarely ketonuria or hyperkelonemia. 5treptozotodn induced diabetes is known
to produce hyperlipidemia (Schein cl al. 1971). Bar-On et 01. (1976) reported
an increase in a~ the plasma lipoprotein fractions, while Blackshear l.t. AI·
berti (1914) reported high levels ofplllSma non·esterified faUy acids (NEFAl
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&lid ketone bodie3 in severely insulin-deficient rats. Hypertriglyceridemia is a
Nmmon occ:urence in severely insulin-deficient rats and the degree ot hyper-
triglyceridemia depends on the duration ofinsulin defidency and diet (Reaven
k Reaven 1914). It has been proposed that the increased fatty acid nux leads
to increased endogenous synthesis of triglycerides (TG) and hence increas~
\'LDL~TG production in these animals similar to the diabetic patients (Nikkiln
& K,kkl 1973).
Von Tol (1971) reported defective clearance as a major fador responsible
for hypertriglyceridemia in type I diabetes. Dec.eased clearance of TO is
I\ttributecl to reduced lipoprotein lipase (LPL) activity (Robinson k Speake
1989). Decreased IIdipose tissue LPL activity has been reported in type I
diabetes (Schnatz & Williams 1963). The lipase activity of liver, adipose tissue
and heart are under hormonal regulation by insulin (Normlt& et al. 1984).
According to O'Looncy e! 01. (1983) decrease in the LPL activity in diabetes
could be due to dectcased symhesis of the enzyme or its activator. Insulin
treatment could testore the activity by stimulating protein synthesis. Insulin
treatment of diabetic rats restores theLPL activity (Schnatz & Williams 1963).
1.5.2 Type II Diabetic Model,
Diabetes, obesity and hyperlipidemill Me frequently Msociatcd pathological
condition,. Most of the type II or non-insulin dependent type of diabetic
patients are obese and hyperlensive. SHR/N·corpu!enl rats arc II good model
for the study of type II diabetes. These corpulent rats are hyperinsulinemic,
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hyperlipidemic, have abnormlll glucose tolerance and develop hyperglycemia
when fed ahigh carbohydrate diet (sucrose) (Michaelis et al. 1984). According
to these investigators sur~rimpo5ing obesily on an already existing insulin·
resistant genetic background could be the cause for the hyper~lycemia.
!wa5e el al. (1986) have reported a new model of type H diabetes with
hyp~rtension. This was experimentalJy de\'eloped by giving various doses of
SZ to the spontaneously hypertensive rats 2 days after birth. This successfu!ly
produced an animal model of mild to severe type II diabf!tes with hypertension.
Genetically obese rodents have ollen been used as models of human obesity
and diabetes (Bray &0 York 1979). Some strains of genetically obese rats have
features resembling type II human diabetes like hyperglycemia and hyperin·
sulinemia (Clark et al. 1983). Obesity can also be induced experimentally by
ventralmedial hypothalamic lesions (\'MH). These animals nre known 10 ex-
hibit hyperglyceMia, hyperinsulinemia along with abnormal glucose tolerance,
indicating the presence of insulin resistance similar to type II diabetic patients
(Jeanrenllud 1977,.
Hyperlipidemia in these animals is primarily associated with endogenous
hypertriglyceridemia and is mainly due to increased VLDL synthesis. Hepatic
overproduction of VLDL and increased secretion or TG or VLDL into the
plasma of obese Zucker rab (Schonfeld &: pneger 1971) and sand rats has
been reported (Robertson eI at. 1973). In the sand rats VLDL sccretion was
reported. to be closely correlated with plasma insulin levels, and insuUn levels
correlated with the body weight (Robertson dol. 1973). VLDL secretion
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rate was proportionaJ to the fattya.cid uptake in rats (Robertson et ai. 1973).
Reaven &t. Greenfield (1981) found thAt liver exposed to elevated levels of
insulin secrete more TO at a given concentration of FFA. They observed that
the hyperinsulinemic ob/ob mouse when treated with small dose of slrepto-
zotodn, had a hepatic TO secretion rate that was similar to that observed in
the lean controls. SimilM observations of elevated TG were noted in hyperisu-
linemic patients with impaired glucose tolerance. (Reaven &t. Greenfield 1981).
Fatty acid levels are increased in obesity an" ,his could be the cause of the
higher TG levels ;n obese patients with impaired glucose tolerance (Sailer el
C1J.1966).
PChE is also increased in the serum and liver of genetkally obese (ob/ob)
rats and diabetic (db/db) mice lIS well as in GTG induced obese mice (Kuuy
et ai. 198tb). Thes(; in\·estigll.tors suggested that an increase in PChE activity
is a result of their incre8Soo caloric intake.
1.6 Objective of the present study
The objecth'e of this study was to find out the reasons for PChE intrease in
Diabetes Mellitus.
The following questions were posed:
(1) is the increase in PChE specific for one type of diabetes or common to
both types?
(2) is there a relationship between serum PChE increl\1ie and abnormal
lipid and lipoprotein metabolism?
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(3) is there a relationship betwten the control or hyperglycemia and serum
PChE activity in diablltes?
(4) does inhibition of PChE affect tipid and tipoprolein metabolism in
diabetic and normal rats?
(5) does the deant.nce of TG .ffect PChE activity In diabetes?
(6) d~ the inhibition of PChE in normal rats result in the accumulation
of chotine or chotinesters in the serum, tim and their excretion in the urine?
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Chapter 2
MATERIALS & METHODS
2.1 Human Study
2.1.1 Subjects
Both type I (insulin dependent 100M) and type II (non-insulin dependent
NIDDM) diabetic patients were studied after obtaining written informed con-
sent. The prot('l~ol \'illS approved by the Human Investigation Committee
(Memorial University of Nfld. St. John's).
Type I patients lVerc recruited from among the patients who attended the
di&betic dink at the Janeway Child Health Centre. The type II diabetic
patients welc recruited from the diabetic clinic at the Grace General Hospital.
The non-diabetic/control subjects (age mah:hed) were chosen at random
(rom the out patients and were con6rmed as !lon-diabetic on the basis of
normal fasting and post meal blood glucose lind normal lipid profile.
2.1.2 Sample collection
Venous blood samples (fasting) were coUected from the control subjects and
patients for the assay of the various biochemical parameters. Blood for glucose
Willi collected in Auoride tubes, in EDTA for HbAle and in plain tubes for
insulin, C-peptide, lipids (triglyceride, TLDL, HDIrC and cholesterol) and
lipoprotein analysis.
2.2 Experimental Animals
Animal experiments were conducted after obtaining apptoVlll from the Presi-
dents Commiltee on Animfll Bioethics and Care (Memorial University of NOd.
51. John's).
2.2.1 Animals
Male Sptllgue-Dawley rats weighing 200-250 g were purcha.sed from Charles
River Breeding Laboratories (Halifax, Nova Scotia). These animals were
housed in the Animal Care Unit of the Health Science Centre at the Memorial
Univf~rsity of Newfoundland, St. John's. Each rat was kept in an individual
cage whirh contained heat treated wood chips for bedding. These cagee were
kept in a light/heat controlled room. AU the animals had free access to food
(Purina rat chow # 5012) and water.
Male CD-I albino mice (Swiss-Webster strain, 60 days old) were purchased
(rom Charles River (Halifax, Nova Scotia). These animals were also housed
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in the Animal Care Unit. Each mouse was kept in an individual c3ge which
contained heat treated wood chips for bedding. AU the animals had rr~ access
to food (Purina mouse chow # 5015) and water.
2.2.2 Induction oC Diabetes with SZ and Alloxan
Fasting (14-15 hr) blood samples were obtained frem the animals prior to inje<:.
tion o( aUoxan/52 to obtain prediabetic levels o( the biochemical parameters o(
interest. Diabetes was induced by a single intraperitoneal injection of freshly
prepared SZ (100 rog/kg body wt.) dissolved in O.OIM disodium citrate buffer,
pH 4.5 (Blackshear & Alberti 1974). For the induction of diabetes with 11.1-
loxar., ~at8 were inje<:ted intrapetitoneally with alloltan (tOO mg/kg body wL)
dissolved in saline. De\'elopment of diabetes WII.S confirmed by the presence
of glycosuria 72 hr after SZ injection. Urine was checked for glucose with a
multistix. Urine was collected from rats in metabolic cages fitted with a steel
collecting funnel and a fine wire mesh screen to retain the feces. The urine
was collected in plastic containers and stored at _20°C until analysed.
2.2.3 Sacrifice oC the animals
Collection of tissues and blood
The a.nimal W&S placed in a 4L beaker containing gauze pads moistened with
Ethrane (2-chloro-l,l,2·triRuoroethyl ether) a.nd covered with II. lid. Within
1-2 min the animal was mildly anesthetited. Blood samples (always 14-15
hr fasting) were colle<:ted by heart puncture using a 5 ml syringe with a 22
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gauge, 25 mm needle. The blood waa allowed to clot at room temperature and
the serum wu separated by centrifuge-tion. After blood coUection the animals
were sacrificed under deep anesthesia. A mid·line incision was made to expose
the required organs. Livers were first perfused with cold normal saline and
blotted dry belween gauze, Epididymal fat pads were cArefully dissected out
avoiding blood vessels, rinsed in saline and blotted dry with filter paper. Sera,
liver and the adipose tissue were stored at ·20oC until ready to usc.
2.2.4 Homogenization of tisDues
Materials
Potassium chloride and Triton X1110 were purchased from Sigma Chemical
Co. USA, "Aiduge" Ultracentrifuge and Beckman TJ-6 centrifuge (Beckman
Instruments, USA). Tissue grinders (Pyrex -# 7727, USA),
Method
Livers were homogenized (with a tissue grinder) in 1% Triton XIOO in 0,155
M KCI solution (4 mllg wet wt. of tissue). The crude homogenate was cen-
trifuged bt 2500 rpm at 4°C for 15 .nin in a Beckman TJ·6 centrifuge. The
supernatant was remove<! with a Pasleur pipette and ultracentrifugcd in a
Beekman "Airfuge" at 110,000 rpm for 5 min at room temperature. The
supernatlUlt was sa.ved to assay pehE activity. Adipose tissue was ground
in a tissue grinder using 2 ml cold water per gram of tissue. The crude
homogenate was centrifuged at 2500 rpm at 4"C for 15 min in II. Beckman
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TJ-6 centrifuge. The infranatant was further ultracenhiluged in a Beckman
"Airfuge" at 110.000 rpm at room temperature for 5 min (Le<=h Ix. Calvert
1968). The dear supernatant was used for the lWay of PChE activity.
2.2.5 Extraction of lipids from liver
Method
Lipids were extracted by homogenizing the tissue (1 g) with 2: 1 chloroform-
methanol (20 mil vfv), such that 1 ml of extract corresponded \0 0.05 g of
the tissue or the homogenate concentration equals 5% (Folch t! al. 1957),
The crude homogenate was filtered through a f/!ot free filter paper. The filtrate
WIIJ washed wHh 0.2 ml of its volume of 0.05% caldum chloride solution, The
two layers were mixed by gentle stirring with a glass rod taking care to avoid
interfacial fluff. The two phases were separated by centrifugation. The upper
phase was removed completely with a. Pasteur pipetle and an aliquot of the
lipid e~tract was evaporated to dryness and analyzed for triglycerides.
2.3 Biochemical Methods
2.3.1 Determination of PC hE activity, in Serum, Liver
and Adipose Tissue
pehE was assayed by the method of Dietz, Rubinstein .It Lubrano (1973)
using propionylthiocholine iodide as the substrate for n,t and mice samples,
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Butyrylthiocholine iodide WM used for human serum and 5,5' dithiobis-(2-
nitro-benroic acid) (DTNB) was the chromogen.
Materials
Propionylthiocho~ne iodide; butyrylthiocholine iodide; 5,5'dithiobis-(2-nitro
benzoic acid) (DTNB); butyrylcholinesterase (horse serum); and Ttis-(hydroxy-
methyl)-aminomcthane(Tris) were purchased from Sigma Chemical Co. (USA).
Reagents
(1) Tris-DTNB buffer (0.05 M), pH 7.4: Tris (6.055 g) was dissolved in 900 mt
distilled water and the pH was adjustt!d to 7.4 with conc. HCI. DTNB (100
mg) was dissolved in this solution and the volume was made up to 1L with
watt!r.
(2) Substrate-buffer solution (made before use): 'I'l:is·DTNB buffer 0.05 M, pH
7.4 (60 ml) was mixed wilh 6 ml of 0.005 M propionyl or butyrylthiocholine
iodide (substrales). To this was added 15 ml of dislilled water and mixed.
Reaction Sequence
Propionylthiocholine + H~O-- Propionic Acid + Thiocholine
Thiocholine +DTNB _ 5-thio-2-nitrobenzoic Acid + Choline
(~olom:l ~ompln)
39
Method
Appropriate aliquots of tissue preparations were added to the substrate-buffer
solution (2.7 ml) and the Tale of change in absorbance of the thioeholine-
DTNB complex formed was r«aIded at 420 nm against a blallk. The tissue
preparations analysed were: human and mite serum (20 Ill), rd serum and
liver homogenate (50 JlI) and rat adipose tissue homogenate (loa pi). The
enzym~ activity was clI.lcub.ted from II standard curve constructed using free
thiocholine iodide as a reference (0.2 to 0.025 J,lmol). The enzyme activity was
expressed in terms of the pffiales of thiocholinc formed in 1 min by I ml of
serum or g wet wt. of tissue.
Preparation of standard curve
BUlyrylthiocholine iodide was the reference standa.rd used. Thiocholine liber-
ated by the action of horse srrum butyr}'lcholinesterase on butyr)'lthiocholine
iodide was the source of free Ihiocholiru~, A stock standard solulion was pte-
pared by dissolving 15.86 mg of butyt)'hhiocholine iodide in 5 ml of distiUed
water to give a concentration of 0.2 ttmol/20 III of solulion. Into a dean
test ~ube was pipetted equal \'olumes of slock standard and horse serum
cholinesterase (1 U/ml). The reaction mixture was incubated for 10 min at
370 C. After incubation was completed, serial dilutions of the enz)'me treated
standard solution was made to givl' 0.2, 0.15, 0.1, 0.05, 0.025 ttffiol of thio-
choline per 20 ttl solution. To 2,7 ml buffer substrate reagent was added 20tll
of standard solutions containing 0.2 to 0.025/lmol of thiocholine and the 0.0
40
was read at 410 nm. The standard thiocholine curve was prepared by plotting
0.0 ver5e8 concentration of thiochoUne in pmole per test volume.
2.3.2 Serum Glucose Estimation
Serum glucose W88 estimated by an enzym&tic method using the IL TEST1'M
Glucose kit (Fisher Scientific Co. USA.) on the Monarch 2000 chemistry au-
toana.lyzer.
Reagents (Provided in the kit)
Glucose reagent was provided as a dry powder which was ra:onstituted with
16.0 ml of deionised water before use.
Composition
Adenosine triphosphate (ATP) ~ 1.79 mM; nicotin&mide adenine dinucleotide
(NtiD) ~ 2.5 mt\fj hexokinase (yta"t) ~ 1000 U/I; G - 6 - PD ~ 1500 UII.
Commercial control serum was run with each set of assay as standard &nd
control.
Reaction sequence
Glucose + ATP --_G-6-P + AOP
G·6-P +NAD+ -------- 6-phosphogluconate +NADH
+ /1-+
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Th~ increase in absofbanc~ at 340 nmdu~ to reduction oC coenzyme NAD+
to NADH is difKtly propoftionaJ to the amount or glucose present in the
sample.
2.3.3 Serum Triglyceride Estimation
Serum Ifiglyceride was estimated on the Monarch 2000 chemistry autoana-
Iyzer using the Peridochrom Triglycerides GPO-PAP (Cal # 701904) kit Crom
Doehrillger Mannheim GmbH Diagnosticll..
Reagents (Provided in the kit)
Composition
(I)Tris buffer: 0.15 M. pIl7.6; MgSOt 11.5 roM; EDTA(disodiumsaJt) JO mM:
4-chloro-pheno13.5 nli\l; Sodium cholate 0.15%;Potassium huacyanorerrll.t~ 6
FM; hydroxypolyethoxJ-n-alkanes 0.12%.
(2)Lyophylisale: ATP ~ 0.54 mM; 4-aminophen-uone 0.35 mM; lipas':! ;:: 3
VIm]; Glycerol phosphftte oxidase (GPO) ~ 2.5 Vlml; GI)'cerol Kinase (GI\)
~ 0.2 U/mli peroxidase ~ 0,15 VIm!.
Preparation of the working reagent: A reagent strip was immersed in a bottle
oC buffer. This was allowed to stand for 5 or more minutes till the reagent
patches turned colorless. Acontrol and standard WM run with each set or assay.
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The control and slandards used wer'! (ommercial serum pre~rations namely,
PreciLip EL, Precinorm and Precilip (Boehringer Mannheim Diagnostica).
Method
Enzymatic hydrolysis of TG with subsequent ddermination of the liberated
glycerol (Bucolo &t David 1973).
Reaction Sequence
Lip...
TQ + 3H,O-- Glycerol + 3RCOOH
Ol,...o\ift...
Glycerol + ATP---Glycerol·3-Phosphate + ADP
Cl,.~.. pbo.ph'.o.id...
Glycerol-3-Phosphate +0, ------OihydroxYACdonephos-
phatc+ 11,0,
11,0, +4·aminophenazone+ 4·chlorophenol--- 4·(~benloquinone-
mono-imino)·phenazone + 21f,O + HCl
2.3.4 Serum Glycerol Estimation
Serum glycerol was measured on the Monarch 2000 chemistry autoanalyzer
using the Test·Combination Triglycerides kit (Cat # 125032), Boehringer
MlI.nnheim GmbH Diagnostica Kit.
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Reagents (Provided in the kit)
Composition
Working reagent: Reagents provided in the kit wert Iyophilised powdeN and
were fKOnstituted with distiUtd water beCore use.
(I) Triethanolamine buffer (0.1 M, pH 7.6j containing MgS04 (4 roM).
(2) NADMIATP/PEP, when reconstituted contained 6, 33 and II roM respe<:-
lively.
(3) Lactate dch)·drogcna.se/Pyruvate kinase (LDII/PK) ~ 800 Vlml, 130
U/m!.
(4) Glycerokinase (GK) ;:: 150 Vim!.
The final reaction mixlures were made as loDows:
Reagent 'A' was made by mixing together 6.0 ml of buffer, 0.5 ml NAOJlI
ATP/PEP ttagent and 0.1 ml LDH/PK reagent
Rellgent 'B' was made by mixing together 6.0 ml of buffer and 0.1 mt or GK.
Concentrations of GI)'ceral standards used were, 0.2 roM and 0.4 MM.
Reaction Sequence
Glycerol + ATP ---GI)'cero].3·Phosphate + ADP
ADP + Phosphoenolpyruvate ---- Pyruvate + AT?
Pyruvate + NADH + H+ ----- Lactate + NAD+
44
The change in absorhancedue to oxidation of NADH to NAD+ at 310 nm
was a direct measure of the concentration of glycerol in the sample.
2.3.5 Serum Cholesterol Estimation
Serum cholesterol was estimated using IL Tesl1M cholesterol kit (Cat # 35215,
Fisher Scientific Co. USA), on the Monarch 2000 chemistry autoanalyzer.
Reagents (Provided in the kit)
Composition
1.aminoantipyrene (4·AAP) 0.9 mM, phenol 21.0 mM, peroxidase (horse radish)
> ~'t,OOO U/I, cholesterol oxidase (microbial) > 1000 VII, cholesterol esterase
(microbial) > 1200 VII.
Method
A modification of the enzymatic melhod established by Allain et af. (1914).
Reaction Sequence
Chol.'I ....I••I••Ut'
Cholesterolesters + /120 ----_ Choleste;ol + Fatty Acid
Cholesterol + O2 ----- Choleslen·3·one + /120 2
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H,O, + 4-am.inoantipyr~n~ + phenol --- quinon~imin~ + H,O
H,O" in the presence ofperoxidlLSe react5 with ph~nol and 4·aminoantipyrene
furming a red colored chromogen. Intensity of the color wu proportional to
the concentration of cholesterol in the sample, whkh was measured at SOO nm.
2.3.6 Serum High Density Lipoprotein Cholesterol Es-
timation (HDt-C)
HD1.-(,) was measured on the Monarch 2000 chemistry autoanalyzer.
Reagents (Provided in the kit)
Precipitant (Cat # 543004) (rom Boehringer Mannheim GmbH Diagnostica.
Working rcagent was prepared by diluting the stock precipitant with 20 ml
water.
Composition
Contains phosphotungstic acid 0.55 mM and MgC/2 25 mM.
Method
Chylomicrons, VLDL (Very low density lipoprotein) and LDL (Low density
lipoprotein) were precipitated by phospholun~5tic acid and magnesium ions.
Centrifugation leaves only HOL in the supernatant (Burstein dol. 1970).
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The cholesterol content or the supernatllnt was determined enzymll.ticaJy on
the Monarch chemistry systems autoannlyzer, like total cholesterol.
2.3.7 Serum Total Low Density Lipoprotein (TLDL)
Estimation
TLDL was estimated in the Monarch 2000 chemistry autoanalyzer.
Reagent Composition
Calcium chloride (CaCI2 1.4 g) and I ml heparin (10,000 U/m!) were mixed
in 383 ml distilled water.
Method
TLDL ie apo-B containing lipoproteins in the serum WBS estimated by mea-
suring the turbidity producl!d by the addition of heparin and CaCl2 reagent to
the sample. Commcrc;al serum samples, like Precilip, Precinorm and Precilip
E.L were used ror the control and standard.
2.3.8 Estimation of Choline and Cholinesters in Serum,
Liver, Adipose tissue and Urine
Free choline was estimated by the Choline oxidase method (McGowan et at.
1983).
Material!
Choline iodide, 4-aminoantipyrine, choline oxidase (Ee 1.1.3.17: &Icaligens
spedes), peroxidase (EC 1.11.1.9: horse radish type 1) and 2-hydroxy-3,5-di
ch(orohenlene sulfonate were purchased (rom Sigma Chemicals Co. USA.
Reagents
(I) Tris/HCI buff'er (50 mM) was made by dissolving 6.0558 g Tris in 900 mJ
H~O and adjusting the pH to 7.8 with HCI. The volume WlI.'I ronde up to 1L
with distilled water.
(2) 4-aminoantipyrine (7.5 mM) was made by dissolving 0.152 g in 10 ml
Tris/HCL buffer (SO roM, pH 7.8).
(3) 2-hydroxy.3,5-dichlorobcnzene sulfonate (30 mM) Wf\.S prepared by dissolv-
ing 0.0795 g in 10 ml Ttill/HCL buffer (50mM, pH 7.8).
(4) Choline oxidase (7 U/ml) was dissolved in Tris/HCL buffer (50mM, pH
7.8).
(5) Peroxidase (30 VIm!) dissolved in Tris/HCL buffer (50 mM, pH 7.8).
Choline reagent
This was made by mixing together in order 2.3 ml reagent (2), 2.3 ml reagent
(3), 5,46 ml reagent (4) and 3.94 ml reagent (5).
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Assay procedure
Into a clean cuvette was pipetted 300 III TriB buffet pH 7.8 and 20 III sample,
standard Ot blank. The D.D. at 510 nm was read until constant. To these
CU\'eltes was added 480 pi o( choline teagent. The contents wete mixed by in-
verting and the change in absorbance was read at 510 nm (or 1-2 min. Choline
iodide WllS lhe ste.ndard Utied (or plotting the standard curve with concentra-
tions ranging (rom 3 to 30 pM of choline. For the delermination of choline
esters 20 ,iI ohample was incubated with 20 Jll horse serum cholinesterase (I
UIml) for 5-10 min at 37°C. An aliquot of the incubated mixture (20 pi) was
assayed (or choline as above. This gives the absorbance for the total choline
i.e. (ftee choline + choUne oblained by the hydrolysis of cholinesters). Thus
the concenbations of the cholinesters were cAlculated by taking the differences
between the total choline and the free choline. The choline concentration was
calculated (rom the standard turve.
2.3.9 Thin Layer Chromatography (TLC)
For qualitative dC!termination of Cholinesters.
Materials
Ammonium reinetkate (BOil), NaCI, acetone, butanol. gla.tial atetit acid,
ethanol (reagcnt grade), KI and bismuth suhnibale were purchased from
Sigma Chemicals Co. USA. Silica gcl G TLC plates (Analtech, inc).
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Reagents
(1) Saturated ammonium reined<ate.
(2) N.el 0.9%.
(3) Dlagendorff's reagent: Consists of potassium iodide (0.11 M) and bismuth
subnitn.te 0.6 mM in 3.5 M acetic add.
(4) Chromatography solvent: Butanol:H~O:Gladal acetic add;Ethanol in the
ratio of 4:3:1:2 (v/v/v/v).
Procedure
Cholinesters in the nmple were predpitated by ammonium reine<:kate. To
0.4 ml rat serum was added 1 ml saturated ammonium reineckate solution.
For the blank 0.4 ml 0.9% NaCI was treated with ammonium reineckate. The
solution was mixed well by vortex for 1 to 2 min and allowed to stand on ice
for 5 min. This mixt~re was centrifuged for 10 min at 3000 xg at 4°C. The
supernatant was discarded and the reineckate precipitate was dissolved in a
known minimum volume of acetone and chromatographed on silica G plates
~sing the solvent system butanol/ H~O/glacial acetic acid/ethanol (4:3:J:2).
Butyr}'lcholine, acetylcholine, propionylcholine and choline were used as ref·
erence compounds. The spots were visualized by spraying with Dragendorff's
reagent.
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2.3.10 Esiimation of Serum C-peptide
Serum C-peptide was determined using the C-peptide kit (Daiichi Radioiso-
tope Labs. Ltd).
Method
Radioimmunoassay method.
Reagents (Provided in the kit)
(I) C-peptide standards of concentration ranging from 0-30 ng/ml.
(2) C-peptide antiserum.
(3) Iodinated C-peptide (mI) 2pCi.
(4) Anli-rabbit•..,.-globulin.
(5) Precipitation stabilizer.
All reagents were lyophilized hence had to be reconstituted before use with
distilled 1}10.
Procedure
All measurements were done in duplicate. The standard solution at patients
serum (1001-11) was transfered into numbered tubes. To this was added 100
pi of iodinated C.peptide (12~1) solution. C·pepticle antiserum (100 pi) was
added to all tubes except the tubes numbered for total count! measurement.
The tubes were gently shaken together with their holders and incubated at
20° C ± 5 for 20 ± 4 hr. After incubation was complete, 500 pi of anti-rabbit
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,-globulin serum was added to each. tube. All tubes were mixed well (within
10 min) on a vortex mixer and incubated (or 30-40 min at room temperature.
After incubation was complete the tubes were cenaifuged at 3000 rpm for 30
min at 4°C. Supernatant WlLS removed by aspiration. Radioa.ctivit)-· of e~h
tube was measured on a gamma counter and the C-peptide concentration was
obtained from a computer program in the counter.
2.3.11 Estimation of Serum Insulin
Serum insulin was determined using the Pharma.cia Insulin RIA Kit.
Principle
Insulin in the sample competes with II. fixed amount of 12~J·labelled insulin
(or the binding sites o( the spedfic antibodil!S. The bound and (ree insulin
are separated by the addition of a Sl!(ond antibody immunoadsorbent. After
centrifugation the supernatant wu aspirated and the radioactivity in the pellet
was measured in a gamma counter.
Reagents (Provided in the kit)
AU reag(!nls were ready to use.
(I) Standard insulin (human) 0-240 IJU1m!.
(2) Antibody.
(3) Insulin·I'~ J (1.0 II Ci).
(4) Dttanting suspension (sepharose-anti-guinea pig IgG).
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Assay Procedure
AU measurements were done in duplicate. Standard and patients SlI.mples
(laO pi) were transfered into numbered tubes. To each tube was added I'~J
(50 pi) followed by 50 pi antibody. The reaction mixture was mixed well
and incubated for 30 min at room temperature. The tubes were centrifuged
10 min at 1500 g and the supernll.tant was removed carefully by aspiration.
The radioactivity of the pellet was measured in II. gamma counter. Insulin
concentration was obtained frv::l the counter by computerised calculation.
2.3.12 Estimation oCGlycosylated Hemoglobin (HbA1c)
HbAlc in the blood was estimated with the Hemoglobin Alc Mini Column
Test kit of Bio Rad (Cat # 19111001).
Materials (Provided in tbe kit)
(1) Hemolysis reagent.
(2) Elution/developing reagent:
(a.) Borate/phosphate buffer pH 6.1.
(b) Phosphate buffer pH 6.1.
(3) Resin columns {weakl}' acidic cation exchange resin).
(4) Calibrators: These were lyophilized human whole blood hemolysatcs.
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Procedure
S~pO'rate columns wer~ set for caiibrators. control and pO'ticnt sample.'!. The
sample hemolp;ate was prepared by mixing together !iOO III hemolysis reagent
und 100111 of the patients sample. This was mrt('xCl:1 anti allnwed to stand
for 10 min. Within GO min of draining the columns, 100 III tcconl'ti!lIte<l
calibrll.tors, controls and patients hemolysatt' WI\S iHlded to the column and
adsorbed on to the resin by allowing it to stand for.'j min. To C/lch column Wl\,.<l
slowly added 4.0 ml elution/developing reagent (boralt'/phnsphate butTer pH
6.7). The eluate was discarded. 10.0 ml elution/c1c\"('I,)ping reagenl (phosphO'te
buffer pH 6.7) was added to each column and the cIliate W'IS sa\'e<l and labelled
'A'. To 11. sel nf tel'! lubes label1('d 'B' was added 10.0 ml elution/developing
reagenl (phosphate buffer pH 6.7) and 20 pi each sample hE'molys~te,control
and calibrator. The contents of tubes lahellt'd A an, 1 were mixed well on
II. \'ortex before reading the absorbance at 415nm. HbA1c concentrations was
calculated from a standard curve.
2.3.13 Electrophoretic Separation of Serum Lipopro-
tein
(a) Polyacrylamide gel electrophoresis (PAGE)
Method
Serum 1ipoproteins were separated on polyacrylamide gel by the method of
Frings, Fosler & Cohen (1971).
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Materials
Tris [lris(hydroxyeth)'l}aminomelhane].Tri1.rna bast': 'rE~tED (~,N.N'.N"t'lra­
methylelhylent'rliamine); acrylarnide (Bio Had); bisarrylamide( N,N'-rnC'thylene-
bisI\cr)'lamide): riboAavin; sucrose; ammo:lium p<'rsulfate and glycine were
obtained from Sigma Chemical Co. (USA) and Sud,ln Black B from Fisher
Scientific Co.
Equipment
Gel lubes ixi5 mm glass tuhcs. Power pack ( Electrotek™ power supply,
Buchler instrumE.'nts N.J.).
Reagents
(A) Separating Gel:
(I) Tris (9.08),0.8 ml Hel and 100 pi TEMED were dissol\'ed in 50 ml H,O.
(2) In 50 mll1,O was dissolved 6.0 g acrylll.mide and 2·10 mg bisacrylamide.
(3) Ammonium persulfll.te (280 mg) was dissolved in 100 ml H20.
Solutions 1,2 and 3 were mixed in the ratio of 1:1:2 (v/v/v).
(B) Stacking Gel:
(I) Tris (5.08 gm) and 0.16 ml of TEMED were dissolved in 100 ml H20 after
the pH was adjusled to 6.7 wilh He!.
(2) Anylamide (2 gm) and 0.5 gm of bisacrylamide were dissolved in 20 ml
/1,0.
(3) Riboftavin (8 mg) was dissolved in 100 ml H,O.
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(,1) Sucrose (20 gm) was dissolved in 5001111,0.
Solutions 1.2,,'Jllnd" were mixed in th~ rlltio of 1:2:1:-1 (v/v/v/\').
(C) Loading Gel:
Slacking gf!! (4 ml) and 0.5 ml working d)'e were mixed just before use.
(OJ Dye solution:
Slack dye solution consisted of 250 mg Sudan Black B dissolved in 30 ml
ethanol. Working dye solution WILS made before use by diluting 1.5 ml stock
dye solution with 3.5 mlll,O.
(E) ChambN Buffer:
Trisfgl)'cine buffer was prepared by dissolving Tris (6.0 g) and glycine (28.8
g) in 800 tnl H20. The pll was adjusted to 8.3 with cone. lleL and the final
volume WM made up to lL with distilled water.
Procedure
To each gel tube was added].O ml freshly prepared separating gel and the top
of the gcl was laYHed with H,O. The gels were allowed to photopolymerize at
room temperature. After polymerization was complete. H~O used for layering
the gels was removed and 100 pI of concentra.ting gel solution WI!.S added to
each tube and the gels wm topped again with H20 and allowed to pol)'merize.
To the polymerized gels were added 50 ,.1 of serum and 200 pi of loading gel.
They were mixed by invertion and the tubcs were layered with chamber buffer,
and allowed to polymerize for 30 min under intense light. The gel tubes were
then inserted into the electrophoretic cell containing buffer. Electrophoresis
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was run for 30 to 40 min at 5 rnA per gel.
(b) Agarose gel electrophoresis
lIumanserum lipoproteins were separated using the Po.ragonLipoprotein (Lipo)
Electrophoresis Kit of 8«kman (PIN 6(5910) USA.
Equipment
Electrophtcsis cell, power pack, sample applicator, wet processor station and
dr)'er, all from Paragon, Beckman USA.
Reagents (Provided in lhe kill
(I) B-2 Barhital buffer pH 8.6 WI\.S made by dis.'IOlving 5,S.diethylbarbiluric
ACid (18.2 g) a.nd 5,5-dieth)'lbarbituric ACid sodium sa.lt in IL H~O.
(2) Lipoprotein lI"orkingstain (O.Oi%): To 165 m! reagent alcohol was added
3 ml Paragon liposlain. To the thloughly mixed solution was adJed deionizoo
11,0 (135ml).
(3) Fixatiw: solution: To IRO rol reAgent alcohol WIS added 90 ml deionized
ll~O and 30 ml ACetic add.
i'l) Desillin solution: To 4.50 ml reagent alcohol WAS added 550 m! deionized
IhO and mixed.
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Procedure
The compartments of the electrophoretic ceU were lWed with 45 ml buffer.
Lipo gels were blotted with the gel bloUer and the template aligned with
position dots on the edges of the gel. Samples were applied into each template
slot with the help of an applicator and stood. for 5 min. The tempi rate W/lS then
blotted and the gels were placed into the gel bridge assembly, which was placed
inlo the electrophoresis cell with a power supply. Electrophoresis was carried
out for 30 min at 100 Volts. Upon completion the electrophoresis gels were
placed in gel frames and immersed in fiXlttive solution for 5 min. They were
then completely dried in the dryer. The dried gels were stained by keeping
in the working stain for 5 min. The excess dye was removed by destaining
the gels for 5 min and finaUy dried in the dryer.The lipoprotein bands were
quantitllted with a densitometer at 600 nm.
2.3.14 Statistics
All values are anal)'sed by sludents 't' test. Pearsons correlation analysis was
done on the dala of type I and type II diabetic patients.
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Chapter 3
RESULTS & DISCUSSIONS
3.1 Human Studies
3.1.1 Serum Pseudocholinesterase activity in Type I
and Type II Diabetic Patients
Aim
The aim of this study was to determine whether serum PChE activity is in-
creased in diabetic patients and whether the increase is specific for a particular
type of diabct<,s or common to both type I and type II.
Results
The levels of PChE activity and concentrations of glucose, lipids, C-peptide,
insulin and HbA 11" in type I and type II diabetic patients were compared with
the controls. Clinical characteristics of the ,Iiabetic patients are summarise<1
Ii!}
in Table 3.1. Approximately equal numbers or male and female subjects were
dose!y matched with regard to age, weight and height.
Tables 3.2 and 3.3 gives a comparison of serum values between the control
and diabetic patients (type II and type I respectively). Diabetics differed
significantly rrorn their age and sex matched controls, Serum pehE activity
was round to be significantly higher (p<O.OOl) in the diabetic patients. The
significant increase in C-peptide in the type II diabetics i.~ consistent with
identifying this gtoUp with the non'insulin dependent type. C.peptide level
was significantly lower (p<O.OOl) in the type I patients which is common to
this type or diabetes. Poor long term glycemic control is indicated by increased
HbAlc levels in these patienls. The '('~'els or serum lipids and lipoproteins, TO
and TLDL were significantly highet in the diabetic patients. Serum cholesterol
level was increased in both the types or diabetes, bul was more significant in
t}'pe I (p<O.OOI). HDL-C was significantly lower in the type II patients, while
in type l there was no ~ign;ficallt change (p=O.600).
Discussion
The present study on th.. diabetic patients reconfirms the observation made
in the 1930's demonstrating an increase in serum pellE activity in diabetes
(Antopol eI af. 193;). Bul these investigators did not provide specific de-
tails regarding the type of diabetes or any contributing fa.ctor(s) respunsible
for the increase in pehE activity in diabetes mellitns. The present study
demonstrates that pehE activity is e1evlLted in both types of diabetes (20%
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in type II and 43% in type 1) as compared to the controls. Type 11 patients
have increased seTum C·peptide le\'els which suggests a certain degree of in-
sensitivity to insulin. Low lel'els of C-peptide in the type I diabetic patients
indicates deCTellSed insulin secretion, characteristic o(this type. HbA1c is also
significantly higher in the diabetic patients suggesting lack of glycemic control.
Decrease in HDL-C is a common finding in patients with elevated VLDL, TG
and in diabetes (Howard HI87). The common factor in both types of diabetes
appears to be hyperJipoproteinemia espeeially hypertriglyceridemia. Increased
serum PChE activity has been reported in type lib and IV hyperlipoproteine-
mic patients (Kutty tl a/. 1!l81 a, hin et 01. 1983) and hyperlipoproteinemia is
known 10 be common in dilLbetes mellitus. There is a good positive correlation
between PChE and TG as indicated by Pearsons correlation analysis which
8M'e P=OA9f1 fot type I Rnd P=O.526 for t)·pe II diabetic patients respectively.
Since the majority of TG is in the form of VJ,OL in the blood this suggests a
retationship between PChE and VLDL, The correlation between serum pehE
and the other "aria-bles like glucose, cholesterol, TLDL and IIDL-C was not
statistically significant,
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TAble 3.1:
Clinical tharaderistics of the patients
Type No Sex Age
y,
Duration
of diabetes
Weighl
Kg
Height
em
IODM 53 M 12.8 ± 0.8 >lyr 48.5 ± 3.3 150.0 ± 3.7
57 F 12,4 ± 0.6 >I)'r 44.2 ± 2.8 ]4~.4: ± 3.1
NIDDM 2O M 59,] ± 2.5 >lyr i7.1 ± 2.9 J70.5 ± 2.4
21 F 45.1 ± '.3 >lyr 66.2 ± 2.7 ]57,3 ± 1.2
Medication a.nd other complications not retarded.
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Table 3.2:
Comparison or serum values between Control
and Type II diabetic patients (NIODM)
Anal)'sis Conlrol(40) Patients(4lt P value
PChE (Ufl) 3222.11 ± 46A 3836 ± 126 0.001
Glucose (mmol/I) US ± 0.07 100'45 ± 0.52 0.001
CoP<P (pm~fI) 266.1i ± 15.8 869.1 ± 82.'1 0.001
Insulin (pmel/I) i8.2 ± 4.2 354.0 ± 80.2 0.002
IlbA 1c (%) .'i.6.; ± 0 ..')0 S.H ± 0.25 0.001
TG(mmoljl) 1.33 ± 0.07 2.58 ± 0.20 0.001
rhol (mmoljl) S.H ± 0.12 6.02 ± 0.21 0.050
TLDL (gfl) 3,47 0.11 4.24 ± 0.22 0.025
HDL-C (mmol/l) 1,40 ± 0.05 1.21 ± 0.06 0.036
LDL·C (mmol/l) 3.32 ± 0.11 3.63 ± 0.16 0.250
f Mean ± SEM .
.. Number or subjects.
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Table 3.3:
Comparison or serum values between Control
and Type I diabetic pllotien15 (lODM)
Analysis Control(22) Patients(IIO)" P "alue
PChE (U/I) 3028.0' ± 95.0 4336.1 ± 70.5 0.001
Glucose (mmol/!) 4.83 ± O.ll 14.59 ± 0.64 0.001
C-pep (pmol/l) 631.0 ± 101 160 ± !l.S 0.001
Insulin (pmol/I) 134.4 ± 1i.l 459.~ ± 35.9 0.001
HbA1c(%) 5.36 ± 0.16 8.57 ± 0.23 0.002
TG (mmol/l) 1.19 ± 0.09 2.15 ± O.Oi 0.001
Chol (mmol/I) 3.59 ± 0.14 4.67 ± 0.01 0.001
TLDL (gil) 1.96 ± 0.09 2.92 ± 0.07 0.001
HDL·C (mmol/l) 1.36 ± 0.09. \.42 ± 0.03 0.600
LDL-C (mmol/l) 1.74 ± 0.12 2.27 ± 0.06 0.001
t ~fe;,.n ±SEM.
• Numberorsubjecis.
3.2 Animal Studies
3.2.1 Type I Diabetic Model
Induction of diabetes with streptozotocin and alloxan
Aim
This experiment was designed to determine a) whether serum PChE a<:livity
increase occurs with induction or hyperglycemia in the experimental animal
that mimics the type I diabetic patient and h) whether Il relationship exists
between serum glycerol, TG a.nd PChE activity.
Results
Table 3.'1 shows" compar;son of serum values of rats before and after induc-
tion of diabetes with 5Z. The difference in the number of animals between the
control (3&) and lest (30) is bC1:11USe a few died during/aner blood coUedion
and a few after the administration of 5Z. Intrapcritoncallldministration of a
single dose (100 mg/kg body wt.) of SZ resulted in 8 significant increase in
serum glucose and serum PChE activity l~ithin 72 hr of the treatment, with
a concomitant increalle in TO, glycerol and TLDL levels. The decreasr. in
cholesterollevel was insignificl\nt (P=O.1IO). while HDL-C decrel\Sed signifi-
CAntly (p<O.05), A decrease of 48% in circulating insulin levels WM observed
in SZ heated rats. Adipose tissue PChE activity W/lS increased significantly
in the SZ diabetic rats (p<O.OOI), while no change in liver PChE activity was
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noted (p=O.076, Table 3.5). Liver TG showed. & significant increase after SZ
administration (p<0.05). The weights of control aorl diabetic rats were similar
at the start of the experiment, but, on development of diabetes the SZ treated
rats lost 12% of their body weight compared to the normals.
Induction of diabett~with alloxan, like SZ significantly increased the serum
glucose level and PChE activity within 72 hr (Table 3.6). Serum TO, choles-
terol, TLDL and glycerol levels were also significanUy elevated.
Discussion
Streptolotocin was the chemical used for the induction of diabetes in all the
experiments except in one. Diabetes wa.s induced with alloxan only in one set of
rats to verify whether increase in PChE activity was consisten'. with chemically
induced diabetes irrespective of the type of diabetogenic agent used.
A 48% decrease in the circulating insulin level indicates damage to the fJ
cell. In previous studies Schein elal. (1971) and Sar·On (1976) observed de-
creases of50% and 60% respectively in the serum insulin levels after treatment
with SZ. Increased serum PChE activity in SZ induced diabetic rats is con·
sistent with the obsevations of Deshmukh (1986) on alloxan induced diabetic
rats. The increase in TG levels in the diabetic rods appears to be a result
of increased VLDL. This assumption is bl15ed on the following reasons, (8)
&ll blood samples were collected after an overnight fast, (b) lipoprotein elcc-
trophoresis did not show the presence of any chylomicrons but gave a dense
pre-j3 lipoprotein (VLDL) band (Fig 3.3) (c) a.nd increased serum TLDL was
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noted (a measure of lipoproteins of density < 1.006, Table 3.4). The in<:rease
in glyc:erollevel oWlred in parallel with the elevation oCTG and TLDL. Glyc-
erol is a. measure oC the degree of lipolysis in the adipose tissue. Hence the
increase of serum glycerol in the diabetic rats indicates inerease<l lipolysis.
Earlier studie" suggested that the increase in VLDL-TG in the diabetic rats
was due to both enhanced VLDL·TG synthesis andsccretion (Nikkila k Kekki
1973). Increased fatty add mobilizalion due to increased lipolysis appears to
be the reason. This agrees well wilh the increase in serum glycerol, TG and
liver TO found in the presenl study in the diabetic rats. Serum PChE activ-
ity increascd together with TG and glycerol, indicating a possible relationship
between PChE activity and VLDL metabolism. Decrease in serum cholesterol
level in the SZ induced diabetic rats appears to be a result of the significant
dl!'Crease in serum IfDL-C concentration (Table 3.4).
The origin of serum PChE is suggested to be from the liver (Silver 1974).
However the liver PChE activity in the diabelic rats did not differ significantly
from the controls (Table 3.5). The reason for this could be thll.t, though PChE
is synthesized in the (h'er, it may be rapidly secreted into the circulation.
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Table 3.4:
Comparison of serum values befote and after induction
of diabetes with StreplolOlodn
Analysis BeCote induction (38) Arter induction (30)" P valu!!
Glucose (mmol/I) !i.a!)! ± 0.21 27.7 ± 1.33,1 0.001
PChE(U/lj '2-13.1 ± 7.2 381.5 ± 11.8 0.002
Insulin (pmal/I) 65.9 ± .1.7 34.8 ± l.05 0.001
TG (mOlal/I) 0.63 ± 0.05 2.43 ± 0.24 0.001
Glycerol (010101/1) 0.:13 ± 0.01 0.52 ± 0.03 0.001
Chol(mmol/I) 1.62 ± 0.06 1.58 ± 0.09 0.;10
TLDL (g/I) O.li ± 0.01 0.27 ± 0.02 0.001
HDlre (mmol/I) lAO ± 0.01 1.J1J ± 0,01 0.041
Weights (g) 259 ± 1,49 229.1 ± 1.36 0.001
t Mean ± SEM.
* Number of animals.
G8
Table 3.5:
Tis~uc levels of TO and PChE in Control
and Diabetic rnt8
Tissue Control(12) Diahctic(8)" P vl\luc
Lim penE 0.901 ± 0.04 1.01 ± 0.03 0.076
1.i\·crTG HI.8S ± 0.68 23.36 ± 1.19 O.O:H
Adipose PChE 0.35 ± 0.01 0..13 ± 0.01 0.001
t Mean ± SEM.
'" Number of "nimllk
Expression of dl\la: liver TG pmolfgm wet wt., liver and adipose
tissue PChE Ilmolfminfg wet wt.
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Table 3.6:
Compl\rison of serum \"l\lues before and after induction
of diauctes with AlIox:an
Anal)'sis Control(26)" Diabctidl6) P value
Glucose (mmol/I) 5.551 0.18 23.2 ± 2.95 0.001
PChE(l'/l) 252.9 10.3 372..1 ± 23.7 0.001
TG (mmol/I) 0.8·1 0.05 l.9S ± 0.13 0.001
Glycerol (mmol/I) 0.30 0.01 0.63 ± 0.02 0.001
Chol (mmol/I) 1.3.) 0.05 l.81 ± 0.07 0.001
TLDL (gil) 0.13 0.00 D.:.! I ± 0.01 0.001
Weight(g} 255 4.20 220.5 ± 2.10 0.002
t Mean ± SEr-,t
* Number of animals.
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3.2.2 Effect of Insulin Treatment on Diabetic Rats
Aim
The aim of the following experiment was to determint whether control of
h)'pcrglycemia with insulin aKeel!! serum PChE activity besides norrnaliting
lipid lel'els.
Results
Figs J.l "nd J.2 illustrete the effects of insulin trclltment and withdrllwal on
diabetic rllt!;. The difference in the number of animals was the result of death~
occuring due to the experimental treatments, Induction of diabetes caused a
lIignilicant increase ill the le,'els of serum glucose, PChE activity, TG, glycerol
And TL.DL, Changes in lICrum IIDL-C and cholesterol levels "tre statistically
insignificant (p=O,330 & 0.610 respecth'ely), Diabetic rats were gi"en 3 units
ofinsulin/day subcutaneousl)' ror a w~k, Arter gl)'cemic conuol was achie,'ed
as detected by mGnitoring urinary glucose, blood was coll!Cted and insulin
treatment was discontinued. Treatment with insulin resulted in a significailt
reduction in the serum glucose level (p<O.OOI), Concomitant with the control
of diabetes the serum lC!vC!ls of (lChE ILCtivity, glycerol and TG also decreased
significantly, while thC! decrC!asC! in TLDL level was not statistically significant
(p=O.820) compared to the diabetic rllts. In contrast, cholesterol and IIDL-C
showed a significant increase (p -0,005). Glycosuria reappeared on the 3td
day of insulin deprivation, Following withdrawal of insulin the levels or serum
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glucose, PChE activity, TO, TLDL, glycerol, cholesterol and HDL·C reverted
to those observed in the diabetic state.
The electrophoretic palterns o( serum lipoproteins obtaincd on 10% poly-
acr)·lamide gels of rat serum isolated beforc and after induction of diabetes and
after treatment and withdrawal of insulin are shown in fig 3.3. A dense VLOL
band (pre-{1 lipoprotein) wll..~ \'isible in the serum isolated from the diabetic rat
and was undoubtedly respon~ilJle for the increased serum TO concenl ration
observed (Fig 3.1). The LDL (;3-lipoprotein) and HDL (a-lipoprotein) bands
were less p,:mounced in the diabetic compared to the normal rat serum. In-
sulin treatr_'lent reduced the VLDI, blind alld increll.l>oo IIDL. Withdrawlll of
insulin intr(!a.~ed the VLDL band Ilglloin with a decruse in HOI, and LOL
bands.
Discussion
The decrease in serum PChE acth'ity after insulin treatment with a concomi-
tant decrease of TG which is essentially assodlloted with VLDL, indicate:; a
close relation between PChE activity and VI,DL. The decrell..!ie in serum gl)'c-
erol concentration due to insulin treatment suggests an inhibition of the ac-
celerated lipolysis in the adipose tissue which is usually found in diabetes.
Therefore the decrea.se of TO with the decref..se in serum g!ycerol is an in-
dication that part of the reason (or hyper-pre-p-Iipoproteinemia or increased
VLDL may be the overproduction of VLDL in the liver. The reduction in
serum TG was more me,rked than the pehE activity in the diabetic rats after
insulin hulment (Fig 3.l). Insulin Ireatment i$ known to activate lipoprotein
lipase (LPL) which facilitatetl 'ie rapid clearance of VLDL-TO from the cir-
culation (Sehanll &. Williams 1!l63). This accounte for the mark«l dC'Cre&Se of
TO in the diabetic rats treated with insulin. Onlhe other hand, though pehE
activity decreased significantly Ilfter insulin treatml'nt it ""M nol &S marked
&S serum TO. The possible relSOn for this could be. tI:at LPL hIlS no effect in
the clearance of pehE from Ihe circulation.
Ahout 60-70% of serum cholesterol is in the form of IlDL-C in lhe rlLu.
Insulin trealment decreased VLDL signific&ntly but Ilt the same time de-
\'lLlell IIDL (Fig 3.3). TM!! explains why, serum cholesterol w&s significantly
(p<O.005) increMef\ in the insulin treated rats.
Withdrawal of insulin del'atecl the serum glucose concentration to almost
that levI:'! obscn·ed before insulin trell.tmenl (Fig 3.1). 5Z is known 10 CAUse
irrC"ersible damage 10 the pAnaeatic fJ cells (Junod tl of. 1969). This is
confirmed by the 48% dccre...~ in circuillting insulin len'ls (Table 3.1) ohsrrved
within ;2 hr after injection of the diabetogenic agent. Serum TG, glycerol
lind TLDL Jell·cIs were also increased aner withdrawal of insulin. Plasma lipid
b·ds are related to the degree of glycemic control (Soscnko dol. 1!l80, Lopcs-
Vitclla. et 01. 1!l8t). PChE activity &00 increases with the reappearance of
hypcrgl)"cemill. and hyperlipidemia.
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Fig 3.3: Electrophoretogram or serum lipoproteins
A - gel showing the lipoprotein pattern of normal rat serum.
S· lipoprotein pattern 72 hr after induction of diabetes with SZ.
C· lipoprotein paltern one week after insulin treatment of diabetic ral.
D· lipoprotein psttern 3 days after withdrawal of insulin treatment.

3.2.3 Effect or Iso·OMPA on Diabetic and Control
Rats.
Aim
The objective of the foUowing study W&5 to det<!rmine whether the inhibition
of PChE IlCtivity in general and spedlically in the adipose tissue can d~rease
lipolysis in the diabetic rat Ihcreby decT('Ilsing the efflux of glycerol and r"uy
acids necessary for the TG and VLDL s)·nthesis. If this were true it would
also indieale that part of the r('llSon for the increl\Sl! in TG and VLDL levels
in diab~tcs mellitus is due to their o\·crproduclion.
Results
Two close levds (17,6 & 8.2 mg/rll.l) oriso-OMrA (specific PChE inhibitor,
from Sigma Chcmicals Co. USA) were lI.dministered to the diabetic rats in-
trapcritoneaUy dissohed in ph,rsiological saline for a period of 6 dRyS. Com-
parisons of the Sl!tum values of the normal tats with diabetic and iso-OMrA
treated diabetic rats are indicated in the Table 3,1. The levels of serum PChE
acth·ity, glucose, TG, TLDL and glycerol were signltlcantly higher in the di-
abetic rats than the controls. while serum cholesterol showed no l'Iignificanl
change (p=O.860). These findings are similar to those observe....' in the pre-
vious experiments (Table 3.4; Figs 3.1 &.: 3.2). At both le\·els of iso-OMPA,
PChE inhibition was highly significant. However the residual PChE activily
al the lower dose of iso-OMPA was twice that of the higher dose level. The
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administration of a high dose of iso-OMPA to the diabetic rats produced &
significant reduction in the serum TG, glycerol, cholesterol &nd TLDL lev-
els compared to the untreated diabetic rats. At lower doses there was also
a significant reduction in the above mentioned variables compared to the un-
treated diabetic rab. But, wh-:n compared to the serum nlues obtained with
the higher dose of iso-OMPA the only llignificant differences found were be-
tween serum glucose, cholesterol and TLDL. Serum glucose was significantly
(p<O.OOS) reduced with the high dose of iso-OMPA treatment, wherelLS the
low dose had no effect o!\ serum glucose level. Liver TG and pehE activity
in the adipose tissue and liver were significantly reduced in the iso-OMPA
treated diabetic rats compared to the untreated diabetic rals (Table 3.8). The
inhibition of PChE activity in the normal rats also resulted in a significant
deuellSe in the serum glycerolllnd TG levels (Fig 3.5), A decrease in liver TG
and PChE activity in both Ih'er and adipose tissue was also noted (Table 3,9),
A second set of diabetic rats (6) were also treated inlraperitoneally with
iso-OMPA (17.2 mg/rat) for 6 days. At the end of the sixth day iso-OMPA
treatment was discontinuc<.! for 3 days to observe the effect of withdrawal of
inhibition of PCIIE acth'ity on glucose, lipid and Iipoprotdn levels in the dia-
betic rats. Fig 3.4 iUustrates the effect of iso-OMPA treatment and withdrawal
on diabetic rats. As in the previous experiments, 72 hr after injection of SZ Il
significant increlLSe in serum glucose, pehE, TO and glycerol was observed. in-
hibition of PChE with iso-OMPA resulted in a significant decrease in glucose,
TG and glycerol. Withdrawal of iso-OMPA treatment caused a significant
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increase in PChE activity along with all increase in serum glucose, TO and
glycerol levels. The reason for the excessive overshoot in serum glucose and
glycerol due to the withdrawal of iso-OMPA is not clear.
The electrophoretogram of serum lipoproteins on 10% polyacrylamide gel
(Fig 3.6) indicated the absence of chylomicrons. A dense pre-p-lipoprotein
band was observed afler induction of diabetes which decreased afler iso-OMPA
treatment. Diabetic and iso-OMPA treated diabetic rat serum showed Pand
a-lipoprotein bands which appeared lighter than the normal serum.
Fig 3.7 shows the electrophoretogram of serum lipoproteins of normal and
iso-OMPA treated tats. Pre-iJ, Pand a-lipoproteins were decreased after the
iso-OMPA treatment of normal rats.
Discussion
Iso-OMPA treatment of the diabetic rats caused a marked inhibition in S(!rum,
liver and the adipose tissue pehE activity (Tables 3.7 & 3.8). A significant
reduction in serum glycerol was also observed. This suggests that pehE in
the adipose tissue may ha\'e a role in lipolysis. The possibility that pehE
behaves like a hormone sensitive lipase was suggested by SzenJzikowki eJ al.
(1961/62) and Colville et al. (ID64). They showed that speeific (iso-OMPA)
and non-specific inhibitors of pehE like neostigmine and ph)'sostigmine at dose
levels sufficient to inhibit pehE activity decreased hormone mediated release
or fatty acid from the rat aorta. Subsequent to the inhibition of lipolysis
with iso-OMPA serum TG and VLDL decreased markedly (Figs 3.4 Il 3.6).
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Decrease in the glycerol and TG levels in the serum (Table 3.7) togeth~r with
a reduction in liver TG (Table 3.8) provides substantial support that VLDL-
TG production is higher in diabetic rats when compllred to the normal rats.
Within a short period of 3 days, withdrawal of iso-OMPA treatment caused
all the serum va.lues to rise almost to those observed in the diubetic state. A
decrease in serum glucose was also observed but only with the higher dose of
iso-OMPA. It is not possible to explain this observation.
Treatment of normal rats with both high and low doses ofiso-OMPA also
dcuused serum TO, VLOL and TLDL, while glycerol did not show any signif-
icant change. This suggcsts that PChE may have a role in VLDL assembly and
secretion f\nd its final transformation into LOL. Eulier studies have imlicated
lI. stablizing effect of PChE on I,DL (Kutty et 01. 1973). The exact biochemical
and molecular mechnnism Il5sociated with the changes in PChE activity and
its relationship to lipid metabolism in generlll and lipoprotein metabolism in
particular needs to be studied thoroughly to explain this finding.
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Tal-Ie 3.1:
Effect or two dose levels or iso-OMPA on dil\belic rats
Analysis
Glucose
Control Diabetic
(Hl" (14)
4.19' ± 0.09 32.i1 ± 1.330
fligher Lower
do~e(i) dose(7)
25.8 ± U128~ 32.14 ± 1.984
(mmol/l)
PChE 230 ± 7.01 440 ± 18.5b 35.83 ± 0.83" 69..1.' ± 1.9·'"
(Ujl)
TG 0.99 ± 0.08 4.6';: ± 0.62" 0.51 ± O.OS" 0.62 ± O.lOb
(mmol/l)
Chol I.2S ± 0.07 \.2 ± 0.J24 0.:J8 ± 0.09S" 0.7 ± 0.22<
(mmol/l)
Glycerol 0.32 ± 0.02 0.72 ± 0.07< 0.39 ± 0.06< 0.37 ± 0.07b
(mmol/l)
TLDL (g/I) 0.12 ± 0.01 0.56 ± 0.12b 0.05 ± 0.02" 0.13 ± 0.02<
t Mean ± SEM.
• Number oC animals.
P values Cor diabetic V5 control; iso-OMPA treated diabetic
vs diabetic rats: a<O.OOI; b<O.005; c<0.05; d= 0.83-0.86.
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Table 3.8:
Tissue levels of TO and PChE in Diabetic
and lso-OMPA treated diabetic rats
Tissues Diabetic ro\ts(8) Iso-QMPA Tteated(7)" P value
Liver PChE LOil ± 0.03 OAO ± 0.01 0.001
Adipose PChE: 0.43 ± 0.01 0.13 ± om 0.001
Liver TO 23.36 ± 1.19 13.50 ± 2.00 0.001
t Mean ± SEM .
.0: Number of animals.
Values arc expressed liver and adipose tissue PChE
J,mol/min/g wet wt.; liver TG pmol/g wet wt.
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TlI.ble3.9:
Tissue levels of TO and PChE in Normal and
lso-OMPA lrf'ated rats
Tissues Normal Rllts(12)
Liver PChE 0.90t ± 0.04
Adipos<! PChE 0.35 ± 0.01
Liver TG 19.85 ± o.Ge
t Mean ±SEM.
lso-OMPA lreated(6)"
0.51 ± 0.03
0.0-1 ± 0.01
16})3 ± 0.86
P value
0.001
0.001
0.001
• Number of animals.
Va],.les arc expressed liver and aJjpo~ lis.~lle PChE
Ilmolfminfgfll'cllVl.; liver TG Jlmolfg wet wl.
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Fig 3.4: Effect of iso-OMPA treatment and withdrawal on diabetic rats
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Fig 3.6: Electrophoretogram of serum lipoprotein
A • gel showing the lipoprotein pattern of normal rat serum.
i3. lipoprotein pattern 12 hr after induction of diabetes with SZ.
C - lipoprotein pattern 6 days after ~OMPA heatment of diabetic rat.
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Fig 3.7: Electrophoretogl'am of !leI'1lDS tiPOPl'oteiu
A • gel showing the lipoprotein pattern or normal rat serum.
S - lipoprotein pattern arter 6 days or is'l-OMPA treatment.
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3.2.4 EfI'ect of Heparin on FChE activity and Lipids
in Diabetic Rats
Aim
The objective or this experiment was to determine whether heparin injection
could decrease serum TO in the diabetic rats and concurrently to evaluate its
effect on serum PChE activity.
Results
Tahle 3.10 shows the comparison of the levels or serum glucose, lipids and
PChE Ilctivity between (1) control &£ diabetic, (2) diabetic and heparin trel\ted
diabetic rats anti (3) diabetic and saline treated diabetic rals.
A marked increase in serum glucose 72 hr Arter SZ lreatment was observed
along with a significant e1e\'/ltion in the levels or PChE activity, TO and TLDL.
No change in HDL-C (p=O.090) and cholesterol levels (p=O.660) was observed
compared to the control. Injection or heparin (500 units) through the tail vein
to 5 dia.betic rats decreased serum TO levels by 85% within 30 min but pehE
acti\'ity, HDL-C, TLDL and cholesterol levels remained unaffected. A rise in
serum glucose was observed which was not significant (p::-:O.630).
Saline trl!atml!nt of the diabetic rat had no effect on the serum pehE
activity or lipid levels. However S{'mm glucose increased significantly (p<O.05).
The rise in the serum glucose le\'els in the heparin and saline treated rats could
be due to the stress of hlmdling.
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Discussion
Serum TO level dKre~ hy 85% within 30 min of heparin administration
wilhout affKting PChE activity. A dtt.rease in TG "as expected since hep-
arin is known to relcase lipoprotein lipase (LPL) (Brunzell, Porte At Bierman
HIm) which h)'drolyses YLDL·TG, thus reducing the I~ood levels ofbolh TO
Ind TG rich·lipoproteins (VLDL) (Robinson &l Speake 1989), No lIignificanl
chanRc in cholesterol (p=O"UO) "nd IIDL-C (p=0.5ID) WI.! observed which
agrees v"ith the earlier rcport of the effects of hcparin tre~tmenl (Arbeeny &
E<ler 1989). These investigAtors also used the 52-diabetic rat model to study
the effect! of heplUin treatment in the serum lipid and lipoprotein levels. They
re<:orded a dKrell.5e of6i% in the scrum TG le\"c! wilhin I:; min of heparin with
no change in glucose and cholesterolle\'els, Th~e nbscn'alions are consislent
with the view that one of the reASllfiS for hypertriglyceridcmia in .liaheles i~
due 10 rrouced clearance nfVLDL-TG (Ru\'en k Rea\'en 1974). Since serum
PChE activity was not affKted by heparin, this indiut<':\ thai its increase ir
Ihe diabetic rats t!; not due 10 the serum le\"el of TG or dKrcased LPL.
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Tabl~ 3.10:
Comparison betwren th~ strum values or Control L! Diabetic and
betwten Diabetic L! Heparin, Saline trtaled diabttit: rals
Analysis Control Diabetic Heparin Saline
0.j9 ± 0.08 4.41 ± O.S- 0.65 ± 0.17- 5.67 ± 1.54 c
1.11 :t: 0.11 1.83 ± O.IIC 1.59 ± 0.18c 1.i9 ± 0.13c
(10)· (10) trealttl(5) treattd(5)
Glucose 6.34' ± 0.33 29.81 ± 1.66 - 31.12 ± 2.1)6' 35.84 ± 1.69'
(mmol/I)
pehE 231.6 ± 18.8 417.0 ± 26.7- 407.4 ± 29.2" -!20.8 ± 41.5c
(U/l)
TG
(mmol/I)
Chol
(mmolfl)
HDIre 1.33 ± 0.08 1.13 ± 0.08t1 1.0-1 ± O.IOC 1.07 ± O.W
(mmolfl)
TLDL (gIl) 0.13 ± 0.02 0.33 ± 0.04- 0.24 ± 0.06 c 0.36 ± 0.08~
t Mean ± SEM.
• Number or animl\ls.
P values: a<O.OOI; b<O.05; d=0.090; c=0.240-0.960.
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3.2.5 Type II Diabelic Model
Aim
The objective or thi:l experiment was to determine whether serum PChE and
TG increlLSc concurrently in the type II diabetic model.
Results
Table 3.11 shows the comparison between (1) the normal and Gold thioglucosc
(GTG) heated mice and (2) GTG treated and GTG+iso-OMPA treated mice.
Each mouse W&II injected GTG (0,5 rog!S body wt) intraperitoneally (Mar-
shall et al. 1955) while the control group was injected with the same volume
or saline. Their weights and food intake was monitored every two days. Two
weeks after the first injection o(GTG, a setc,ad injection orihe same dose was
given to the same mice. Two weeks later the GTG trealed mke were allowed
water containing 10% sucrose end normal mouse chow tor another two weeks.
At the start o( the experimcnlailthe mice weighed $7·39 g. but at the end of
the experiment the GTG treated mice gained an average of 40% more weight
than the untreated. A striking elevation (72%) in the serum insulin level was
also noted in the GTG treated animals fed 10% sucrose with a concomitant
risc in the levels of PChE activity, TG, TLDL, glycerol and HDL·C compared
to the controls.
Serum PChE Il.Ctivity was 91% inhibited within 24 !it after a single in-
traperitoneal injection of iso-OMPA (17.6 mg) of the GTG treated mice. A
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sisnifiu.nt dKrease in serum TG, TLDL, and &!ycerol wu also observed (Table
3.11). The decreasoe in serum &IUCOIe concentration was insignifiunt (p=O.OBG)
while no change in the HDL-C and chole5tero! levels was obsen'ed,
GTG significantly increased liver PChE activity but had no effKt on adi·
pose tissue PChEaclivity (Table 3.12). lso-OMPA treatnlent ofGTG heated
:nice caused total inhibition in adipose tissue PChE activity and 81% inhibi-
tion in the liver.
Discussion
GTC has been used experimentally to produce obesil)', These animals are
known to exhibit hyperglyc.emia, hyperinsulinemia along with abnormal ;Iu-
case tolerance indica.ting the presence of insulin resistance similar to type II
diabetic patients (Jellnrenaud 1977). Simil"l to the type I diabetic model,
induction of diabetes with GTG caused an increase in the levels of serum
flChE activ::y along "ith TG, glycerol and TLDL. However, unlike tbe type
I diabetic ra' model, these animals gained weight. Hyperphagia is a factor
responsible for the dC\'elopment of obesity and diabetes in this model. h.sulin
le"'els were much higher in the GTG treated mke compared to the controls
(Table 3.11). Increase in VLDL and TG in these animals are a Jesuit ofbalh
excess food in lake and incre&SCd m,jbiliz"lion of fatty acids. Increase in PChE
activity has been demonslt"tedin the genetically diabetic mice (db/db) (Kutly
el 01. 1981b) and Zuchl Cal rals (Kutly et oi. 1984); both are models oC type
IJ diabetes. Treatment with iso-OMPA or the GTG induced diabetic mice,
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dKreased gl)'terol, TO and TLDL similar to SZ diabetic ratl. These results
suggest that increase in PChE activity may be related to hyperlipoproteinemia
and spC!Ci&lly to overproduction of VLDL-TO.
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Table 3.11:
Comparison between ContIol, GTG and
GTG + iso-OMPA treated mice
Analysis Control(12) GTG(8) GTG+
i>o-OMPA(IO)"
Gluco:;e mmol!1 10.99t ± 0.88 16.4.0 ± 2.82 c 11.43 ± 1.36 ~
PChE U/I 3650 ± 166 4856 ± 307 b 427.5 ± 29.2"
TGmmoi/1 1.53 ± 0.19 3.56 ± 0,44b 1.08 ± 0.11-
Chol. mmol!1 3.37 ± 0.22 4.14 ± 0.27c 4.96 ± 0.41~
TLDL g/I 0.74 ± 0.16 2.19 ± 0.29' 0.68 ± 0.07·
Glycerol mmolfl 0.92 ± 0.06 1.47 ± 0.09' 0.74 ± 0.06C
HDL-C mmol!1 3.61 ± 0.21 4.46 ± 0.26( 5.52 ± 0.49"
Insulin pmol/l. 61.0 ± 6.70 221.5 ± 22.0· ND
t Mean ± SEM.
• Number or animals.
ND-Not done as sample quantity was insufficient.
P values: a<O.OOI; b<0.005; c<O.05; d= 0.08-0.12.
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Table 3.12:
CompMison of tissue PChE between control, GTG treated
and GTG + iso-OMPA treated mice
Tissues Control(6) GTG(6) GTG+
;""OMPA(6)'
Livef 1.621 ± 0.15 2.82 ± 0.24~ 0.55 ± 0.08~
Adipose 0.30 ± 0.02 0.2 ± 0.0294
I Mean ± SEM.• Number of animaJ~.
P values: b<O.OOl, a<0.240.
Q.PChE activity not detected.
Values are expressed as: liver and adipose tissue PChE
p.mr!lfminfg wet wt.
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3.2.6 Effect of inhibition of PChE activity in normal
rats
Aim
The aim of the presen~ study W!lS to determine whether the inhibition of PChE
activity in normal rat! caD cause an accumulation ofcholine or cholinester! in
the serum Ilnd adipose tissue or influen(c thl!ir excrl!tion in the urine.
Results
The effects of inhibition of PChE activity on choline and cholinester levels
in serum, U\'er and urine are reported in Table 3.13. Normal rats (5) wl!re
injected intraperitoneally with iso-OMPA (5 mg/kg body wt.) for a period of 5
days, Control rats received the same volume of physiological saline. lso-OMPA
treatment produced almost 70% inhibition in serum and 80% in the! liver PChE
activity in these animals, PChE activity was much lower when measured.
with butyrylthiocholine (BTC) a~ :mbstrate (ompared to propionylthio(holine
(PTC). No PChE activity Wft! detected with BTC M substrate in the serum
of i,()'OMPA rab. Also no statistkaUy significant dilferen(e WM O~IVed
in the choline and cholinester [e!vels in the liver, serum or urine between the
lest and (ontral rats. Qualitative determination of cholinesters by thin layer
chromatography (TLC) indicated that (holinestcr substrales were not present.
The cholinesters from the samples were precipitated with aqueous ammonium
reineckate, The precipita.tes were dissolved in acetone and chroma.tographed
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on siUc8. G plates. Butyrylcholine. acetylcholine, propionylcholine and choline
were used as reference compounds. The spots were visualized by spraying with
Dragllndrofl"s reagent.
Discussion
Whitlllker (1951) suggested that butyrylcholine ma.y be the hue lubstrate for
pehE as it is hydrolysed more rapidly than "ny other choline ester. Similarly
Clitherow ef al. (1963) postuhlted that PChE may be involved in the hydrol·
ysis of BuCh which is II. toxic compound, that is formed from Butryl-CoA and
choline during fatty add metabolism in the lim. Funnel &: Oliver (1965)have
speculated that PChE was involved in the homeostatic mechanism controUing
the level of choline in the plasma and acetyl choline in the brain. They made
this hypotht'Sis on the assumption that PChE hydrolyzed cholinesters, thereby
controlling plnsm/\ choline le\·els.
If the true biological function of PChE was \0 hydrolize choline esters, then
its inhibition should have caused an accumulation of choline or ch(\line esters
in tissues or all incre&Sf:d excretion in the urine. Such Il finding would ha\"e
been consistent with the role proposed by Clitherow €I al. (1063) in regald to
lipid metaboli~m and choline homeostasis by Funndl €I al. (1965). Butfrom
these results it is c1ellr that no qllalitative or quanlitati\'e a.lteration of either
choline or choline ester in serum, liver or urine was produced by the in vivo
inhibition ofrChE.
Based on these findings it appears that the biological fnnction of this en-
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zyme is unrdated to ils cholinester hydrolysing properly.
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T.ble 3.13:
Effect of inhibition of PChE activity on choline and choUnestel'
levels in liver, strum ud urine of rau
Sample Choline Cholinester PChE (BTC') PChE(PTC')
Liver
Control(5)· O.9I1 ± 0.08 0.15 ± 0.02 0.55 ± 0.07 1.47 ± 0.14
Tes' (5) 0.97 ± 0.10 0.13 ± 0.0\ 0.18 ± 0.02" 0.27 ± 0.01-
Serum
Control(6) 61.1 ± 13.1 40.6 ± 10.1 67 ± 1.78 336 ± 16.8
Tes'(5) 19.5 ± 16.4 39.5 ± 9.0 93:1 ± 9.03-
Urine
Control(5) 25.0 ± 4.0 2o.s ± 2.7
NO NO
Tes' (5) 70.1 ± 3.5 11.9 ± 3.4
I Butyrylthiocholine, ~ Proplonylthiocholine.
I Mean ± SEM.· Number of animals.
a (p<o.oS). NO-Not done. o-PChE activity nol detected.
Expression ofdata: Serum and urine chotine and cholincster mmol/lj liver choline
and cholineflter mmol/g wet WI; PChE activity of serum II mol/min/I and tiver p
mol/mm/s wet wt.
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Chapter 4
CONCLUSIONS
In 1937 it was observed that serum PChE activity W/IS increased in the blood
o£patienls with diabetes mellitus, but there has been very little progress made
since to explain this ohscc\'ation. Furthermore, no specific fundion(s) hs been
assigned to this enzyme.
In the present study. a positive correlation has been found between serum
pehE activity and TG concentrations in both type I l!I.nd type II diabetic
pl\lients. Several repe.ts in the litclaLure have suggested that pehE is involved
in ~pid metabolism. For example, increased. pehE activity has heen reported
to occur in humtlns with type lib and type IV hyperUpoproteinemia (Kutty el
al. 1981ai Jain tl al. 1983), genetically ob/ob and db/db mice (Kuuy et 01.
198tb) and zucker (at rata (I\utty el oi. 1984).
Si.nce abnormal lipid metabolism, involving TG and VLDL, is commonly
found in p~til'!nb with diabetes mellitus (Howard 1987) it WII.5 of interest to
detetlfiinL'; to what extent PChE could be correlated with lipid metaboHsm in
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the diabetic state. This has been investigattd with animal model! of type I
and type II diabetes mellitus.
Severe hyperglycemia, induced by SZ or aUoxan treatment of rats, produced
mll.rked elevations in serum TG, TLDL and glYl::crol conc.entrations as well as
PChE activity. When the hyperglycemia was controlled by the administration
or insulin, serum glucose, lipids and lipoprotein concentrations rei-urned to
normal. PChE activity in the serum was also reduced in parallel.
The fluctuation in the level of serum glYl::ero! was or particular interest since
it gives a measure or the degree o( lipolysis in the adipose tissue. An innease
in hormone mediated lipolysis is also known to occur in diabetes mellitus. In
addition, LPL activity is known to be reduced in the absence of insulin and
to be activaled by heparin in diabetic animals (BrunzeU, Porte &l: Bierm8n
1979). Heparin administration produced a marked decrease in serum TG in
the pr~sent study, however, scrum PChE activity WllS not altered.
The type II diabctk model (Gold thiogluwse treated mice) also showed
parallcl changes in both serum PChE aclh'ity and Upid concentrations with
the development or hyperglycemia.
The effect of PChE inhibition, was studied by administration or iso-OMPA
to diabetic and control rats. Diabetic rats showed a reduction in serum levels
or TG, TLDL and glycerol. The (aU in glywol indicates reduced lipolysis of
adipose twue TG, which may be related to inhibition or PChE activity in this
tissue (or a direct effect o(iso-OMPA on the hormone sensitive Iipl\SC 7).
Normal rats treated with the PChE inhibitor (iso-OMPA) also showed a
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significan~ decrease in serum lipids and TLDL as previously reported by Kutty
f.l al. (1971). I~OMPA treatment of diabetic mice showed similar changes
to the diabetic rats.
Speculations on pouible biological fundion(s) of PChE (Fig 4.1).
It ill evident from the results presented in this thesis that there ill a close
relationship between the levels of PChE a.etivity and VLDL in type I and
type II diabetes and hyperlipoproteinemia. When PChE was inhibited with
iso-OMPA, there was no demonstrable accumulation of cholinester substrates
either in the serum or tissues. This suggl!S1s that the fundion of PChE is
unrelated to it! cholinester hydrolysing properties. So, the question is what
other function(s) could it have? It may be associated with VLDL metabolism.
The failure to inhibit PChE activity with heparin indicates that it is not
involved in the clearance of VLDL·TG from the circulation. Therefore, it may
be involved in the synthesis and secretion ofVLDL. Overproduction ofVLDL is
known to occur in diabetes mellitus of both types (Nikkila Al Kekki 1973). The
PChE inhibitor, iso-OMPA, is thought to be sp«ific for this enzyme, therefore
in the absence of other known effects, the decrease in VLDL produced in the
blood may be considered as related to PChE activity.
The increase in PChE activity ill thought to be I\SSOciated with VLDL
synthesis in both types of diabetes rather than FA synthesis, since the source
of FA is dilTerent in types I and II diabetes. As shown in Fig 4.1, hyperphagia
in type II diabetes leads to increased synthesis of FA, TO and VLDL, whereas
in type I therE' is increased mobilization of FA from adipose tissue stores. In
lOS
adipost tissue, inhibition of PChE appears to affKt lipolysis as indicated by
the fan in plasma. gl)'ceroJ. This sugge!b that PChE may have a Cunclion
similar to hormone sensitive lipa.se (US Lipase).
It is obvious Crom the above discussion that there are still many questions
to be answered concerning the possible CuncUon(s) oC Pseudocholinestera.se.
It is, however, evident that PChE could serve M a useCul marker to detect
abnormal lipid metabolism particularly in the diabetic patient!.
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